WO2005051296A2 - Fused ring dicationic anti-protozoan agents and their prodrugs - Google Patents

Fused ring dicationic anti-protozoan agents and their prodrugs Download PDF

Info

Publication number
WO2005051296A2
WO2005051296A2 PCT/US2004/038896 US2004038896W WO2005051296A2 WO 2005051296 A2 WO2005051296 A2 WO 2005051296A2 US 2004038896 W US2004038896 W US 2004038896W WO 2005051296 A2 WO2005051296 A2 WO 2005051296A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
aryl
alkyl
bis
compound
Prior art date
Application number
PCT/US2004/038896
Other languages
French (fr)
Other versions
WO2005051296A3 (en
Inventor
David W. Boykin
Richard R. Tidwell
David W. Wilson
Reto Brun
Reem K. Arafa
Chad E. Stephens
Original Assignee
University Of North Carolina At Chapel Hill
Georgia State University Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of North Carolina At Chapel Hill, Georgia State University Research Foundation, Inc. filed Critical University Of North Carolina At Chapel Hill
Priority to EP04811591A priority Critical patent/EP1689705A4/en
Priority to JP2006541427A priority patent/JP2007513888A/en
Priority to CA002547972A priority patent/CA2547972A1/en
Priority to AU2004292992A priority patent/AU2004292992A1/en
Publication of WO2005051296A2 publication Critical patent/WO2005051296A2/en
Publication of WO2005051296A3 publication Critical patent/WO2005051296A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the presently disclosed subject matter relates to methods of combating microbial infections with dicationic compounds. More particularly, the presently disclosed subject matter relates to methods of combating microbial infections with fused ring dicationic compounds, and to the novel compounds themselves.
  • Na 2 SO 4 sodium sulfate
  • NBS ⁇ /-bromosuccinimide
  • T. br. Trypanosoma brucei rhodesiense
  • TLC thin-layer chromatography
  • Pentamidine has been used clinically against African trypanosomiasis, antimony-resistant leishmaniasis, and P. carinii pneumonia. See, e.g., Apted.
  • Ri and R 2 are each independently selected from the group consisting of H, alkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl;
  • m and n are integers from 0 to 3, provided that when m is zero, Ri is an implied hydrogen, and when n is zero, R 2 is an implied hydrogen;
  • p and q are integers from 0 to 1 ;
  • a and A' are each independently selected from one of:
  • R4, R 5 , Re, R 7 , and R & are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; or R 5 and Re together represent a C 2 to C 10 alkyl, hydroxyalkyl, or alkylene; or R 8 is Re — N R, wherein: Rg and R 10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R 11 is selected from the group consisting of H, alkyl, and aryl.
  • the presently disclosed subject matter relates to a pharmaceutical formulation comprising a compound of Formula I in a pharmaceutically acceptable carrier. In some embodiments, the presently disclosed subject matter relates to a method of treating a microbial infection, comprising administering an effective amount of a compound of Formula I to a subject in need thereof. In some embodiments, the presently disclosed subject matter relates to the use of an active compound as described hereinabove (i.e., a compound of
  • Formula l)forthe preparation of a medicament for treating a microbial infection provides compounds that are useful in the treatment of microbial infections.
  • the presently disclosed subject matter provides pharmaceutical formulations for use in the treatment of microbial infections.
  • the presently disclosed subject matter provides methods for treating microbial infections.
  • alkyl refers to C 1 - 20 inclusive, linear (i.e., "straight-chain"), branched, or cyclic, saturated or at least partially and in some cases fully unsaturated (i.e., alkenyl and alkynyl) hydrocarbon chains, including for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, and allenyl groups.
  • Branched refers to an alkyl group in which a lower alkyl group, such as methyl, ethyl or propyl, is attached to a linear alkyl chain.
  • Lower alkyl refers to an alkyl group having 1 to about 8 carbon atoms (i.e., a C-i- ⁇ alkyl), i.e., 1 , 2, 3, 4, 5, 6, 7, or 8 carbon atoms.
  • Higher alkyl refers to an alkyl group having about 10 to about
  • alkyl refers, in particular, to C- ⁇ - 8 straight-chain alkyls. In other embodiments, “alkyl” refers, in particular, to Ci -8 branched-chain alkyls. Alkyl groups can be optionally substituted with one or more alkyl group substituents, which can be the same or different.
  • alkyl group substituent includes but is not limited to alkyl, halo, arylamino, acyl, hydroxyl, aryloxyl, alkoxyl, alkylthio, arylthio, aralkyloxyl, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl.
  • nitrogen substituent is hydrogen, lower alkyl (also referred to herein as "alkylaminoalkyl”), or aryl.
  • aryl is used herein to refer to an aromatic substituent that can be a single aromatic ring, or multiple aromatic rings that are fused together, linked covalently, or linked to a common group such as a methylene or ethylene moiety.
  • the common linking group also can be a carbonyl as in benzophenone or oxygen as in diphenylether or nitrogen as in diphenylamine.
  • aryl specifically encompasses heterocyclic aromatic compounds.
  • the aromatic ring(s) can comprise phenyl, naphthyl, biphenyl, diphenylether, diphenylamine and benzophenone, among others.
  • aryl means a cyclic aromatic comprising from about 5 to about 10 carbon atoms, i.e., 5, 6, 7, 8, 9, or 10 carbon atoms, and including 5- and 6-membered hydrocarbon and heterocyclic aromatic rings.
  • the aryl group can be optionally substituted with one or more aryl group substituents which can be the same or different, wherein "aryl group substituent" includes alkyl, aryl, aralkyl, hydroxyl, alkoxyl, aryloxyl, aralkyloxyl, carboxyl, acyl, halo, nitro, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acyloxyl, acylamino, aroylamino, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylthio, alkylthio, alkylene, and -NR'R", wherein R' and R" can be each independently hydrogen, alkyl, aryl, and aralkyl.
  • aryl groups include but are not limited to cyclopentadienyl, phenyl, furan, thiophene, pyrrole, pyran, pyridine, imidazole, benzimidazole, isothiazole, isoxazole, pyrazole, pyrazine, triazine, pyrimidine, quinoline, isoquinoline, indole, carbazole, and the like.
  • a dashed line representing a bond in an aryl group indicates that the bond is either present or absent depending on the number of atoms comprising the aromatic ring and, in the case of a heterocyclic aromatic ring, the identity of the heteroatom.
  • substituted alkyl and “substituted aryl” include alkyl and aryl groups, as defined herein, in which one or more atoms or functional groups of the aryl or alkyl group are replaced with another atom or functional group, including for example, halogen, aryl, alkyl, alkoxyl, hydroxyl, nitro, amino, alkylamino, dialkylamino, sulfate, and mercapto.
  • acyl refers to an organic acid group wherein the -OH of the carboxyl group has been replaced with another substituent (i.e., as represented by RCO — , wherein R is an alkyl or an aryl group as defined herein).
  • RCO substituent
  • acyl specifically includes arylacyl groups.
  • Specific examples of acyl groups include acetyl and benzoyl.
  • Cyclic and “cycloalkyl” refer to a non-aromatic mono- or multi-cyclic ring system of about 3 to about 10 carbon atoms, i.e., 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms.
  • the cycloalkyl group can be optionally partially unsaturated.
  • the cycloalkyl group can be also optionally substituted with an alkyl group substituent as defined herein, oxo, and/or alkylene. There can be optionally inserted along the cyclic alkyl chain one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms, wherein the nitrogen substituent is hydrogen, lower alkyl, or aryl, thus providing a heterocyclic group.
  • Representative monocyclic cycloalkyl rings include cyclopentyl, cyclohexyl, and cycloheptyl.
  • Multicyclic cycloalkyl rings include adamantyl, octahydronaphthyl, decalin, camphor, camphane, and noradamantyl.
  • Alkoxyl or “alkoxyalkyl” refer to an alkyl-O- group wherein alkyl is as previously described.
  • alkoxyl as used herein can refer to C ⁇ -2 o inclusive, linear, branched, or cyclic, saturated or unsaturated oxo-hydrocarbon chains, including, for example, methoxyl, ethoxyl, propoxyl, isopropoxyl, butoxyl, f-butoxyl, and pentoxyl.
  • Aryloxyl refers to an aryl-O- group wherein the aryl group is as previously described.
  • aryloxyl as used herein can refer to phenyloxyl or hexyloxyl, and alkyl, halo, or alkoxyl substituted phenyloxyl or hexyloxyl.
  • Aralkyl refers to an aryl-alkyl- group wherein aryl and alkyl are as previously described. Exemplary aralkyl groups include benzyl, phenylethyl, and naphthylmethyl.
  • “Aralkyloxyl” refers to an aralkyl-O- group wherein the aralkyl group is as previously described. An exemplary aralkyloxyl group is benzyloxyl.
  • “Pialkylamino” refers to an -NRR' group wherein each of R and R' is independently an alkyl group as previously described.
  • Exemplary alkylamino groups include ethylmethylamino, dimethylamino, and diethylamino.
  • Exemplary alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, butyloxycarbonyl, and f-butyloxycarbonyl.
  • An alkoxycarbonyl group can be further represented by the following structural formula: O II — C-O-R wherein the "R" group represents an alkyl group as defined hereinabove.
  • alkoxycarbonyl group also can be referred to as an "alkyl ester" group.
  • R is an ethyl group and the alkoxycarbonyl group comprises the following formula: O II — C-0-CH 2 CH 3
  • “Acyloxyl” refers to an acyl-O- group wherein acyl is as previously described.
  • Acylamino refers to an acyl-NH- group wherein acyl is as previously described.
  • “Aroylamino” refers to an aroyl-NH- group wherein aroyl is as previously described.
  • Alkylene refers to a straight or branched bivalent aliphatic hydrocarbon group having from 1 to about 20 carbon atoms, i.e., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms.
  • the alkylene group can be straight, branched or cyclic.
  • the alkylene group can be also optionally unsaturated and/or substituted with one or more "alkyl group substituents.” There can be optionally inserted along the alkylene group one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms (also referred to herein as "alkylaminoalkyl”), wherein the nitrogen substituent is alkyl as previously described.
  • Exemplary alkylene groups include methylene (-CH 2 -); ethylene
  • alkylene group can have about 2 to about 3 carbon atoms and can further have
  • amino refers to the -NH 2 group.
  • halo refers to fluoro, chloro, bromo, and iodo groups.
  • hydroxyl refers to the -OH group.
  • hydroxyalkyl refers to an alkyl group substituted with an -OH group.
  • mercapto refers to the -SH group.
  • oxo refers to a compound described previously herein wherein a carbon atom is replaced by an oxygen atom.
  • nitro refers to the -N0 2 group.
  • thio refers to a compound described previously herein wherein a carbon or oxygen atom is replaced by a sulfur atom.
  • sulfate refers to the -S0 4 group.
  • X and Y are each independently selected from the group consisting of CH, CH 2 , N, CO, O, S, and NR 3 , wherein R 3 is selected from the group consisting of H, alkyl, aryl, alkoxyl, and aryloxyl, and Y can be present or absent;
  • R-i and R 2 are each independently selected from the group consisting of H, alkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl;
  • m and n are integers from 0 to 3, provided that when m is zero, Ri is an implied hydrogen, and when n is zero, R 2 is an implied hydrogen;
  • p and q are integers from 0 to 1 ;
  • a and A' are each independently selected from one of:
  • R 4 , R 5 , Re, R7, and R 8 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; or R 5 and R & together represent a C 2 to C 10 alkyl, hydroxyalkyl, or alkylene; or Re is R 9 — N ⁇ R 10 wherein: R 9 and R 10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R 11 is selected from the group consisting of H, alkyl, and aryl.
  • X is CH 2 and Y is absent.
  • the fused-ring structure comprises 9H-fluorene.
  • a and A' are each independently
  • R and R are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and Re is selected from the group consisting of aryl and
  • R 9 and R ⁇ 0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R 11 is selected from the group consisting of H, alkyl, and aryl.
  • a and A' are in the 2- and 7-positions of the 9H-fluorene ring.
  • m and n are both zero and R 7 is H.
  • R 4 is H and Re is phenyl.
  • R 4 is H and R 8 is 2-pyridyl.
  • R 8 is
  • Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R1 1 is selected from the group consisting of H, alkyl, and aryl.
  • R 4 and Rg are each H.
  • R 4 is ethoxycarbonyl and R 9 is H.
  • Rio is H.
  • R 10 is methyl.
  • 0 isopropyl.
  • R-io is methoxyl.
  • Rio is iso-butoxyl.
  • the fused-ring structure comprises 9H-fluoren-9- one.
  • a and A' are each independently
  • R 4 and R 7 are each independently selected from the group consisting of H alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R 8 is selected from the group consisting of aryl and R 9 — N ⁇ R 10 wherein: Rg and R1 0 are each independently selected from the group consisting of H, alkyl, aryl, and -OR- ⁇ ; and wherein: R 11 is selected from the group consisting of H, alkyl, and aryl.
  • a and A' are in the 2- and 7-positions of the 9H-fluoren- 9-one ring.
  • m and n are both zero and R is H.
  • R 8 is
  • Rg and R ⁇ 0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R 11 is selected from the group consisting of H, alkyl, and aryl.
  • Rg and Rio are both H.
  • R 4 is H.
  • R 4 is ethoxycarbonyl.
  • the fused-ring structure comprises 9,10- anthraquinone.
  • a and A' are each independently
  • R 4 and R 7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R 8 is selected from the group consisting of aryl and R 9 — N ⁇ Rl ° wherein: Rg and R1 0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
  • n and n are both zero and R 7 is H. In some embodiments, R 8 is
  • Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R 11 is selected from the group consisting of H, alkyl, and aryl.
  • Rg and Rio are both H.
  • R is H.
  • X is N and Y is CH.
  • the fused-ring structure comprises acridine.
  • a and A' are each independently
  • R 4 and R 7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R 8 is selected from the group consisting of aryl and Re — N ⁇ R 10 wherein: Rg and R ⁇ 0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R 11 is selected from the group consisting of H, alkyl, and aryl.
  • a and A' are in the 3- and 6-positions of the acridine ring.
  • m and n are both zero and R is H.
  • R 8 is
  • Rg and R-io are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
  • Rg and R- ⁇ 0 are both H.
  • R 4 is H.
  • the compound is selected from the group consisting of: 2,7-bis-guanidino-9H-fluorene; 2,7-bis- guanidinofluoren-9-one; 2,7-bis-guanidinoanthraquinone; 3,6-bis- guanidinoacridine; 2,7-bis-( ⁇ /"-ethoxycarbonyl)guanidino-9H-fluorene; 2,7- bis(A/"-ethoxycarbonyl)guanidinofluoren-9-one; 2,7-bis( ⁇ /"-ethoxycarbonyl- ⁇ /- methyl)guanidino-9H-fluorene; 2,7-bis( ⁇ /"-ethoxycarbonyl- ⁇ /- isopropyl)guanidino-9/-/-fluorene; 2,7-bis( ⁇ /"-eth
  • the compound of Formula I comprises a pharmaceutically acceptable salt.
  • the salt is a hydrochloride salt.
  • compounds disclosed herein are prodrugs.
  • a prodrug means a compound that, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this presently disclosed subject matter or an inhibitorily active metabolite or residue thereof.
  • Prodrugs can increase the bioavailability of the compounds of the presently disclosed subject matter when such compounds are administered to a subject (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or can enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to a metabolite species, for example.
  • a biological compartment e.g., the brain or lymphatic system
  • a number of the compounds (e.g., compounds 7a, 7b, 7c, 7d, 8c, and 10) discussed in Example 2 are prodrugs.
  • C. Pharmaceutically Acceptable Salts Additionally, the active compounds of the presently disclosed subject matter can be administered as pharmaceutically acceptable salts.
  • Such salts include the gluconate, lactate, acetate, tartarate, citrate, phosphate, borate, nitrate, sulfate, and hydrochloride salts.
  • the salts of the compounds described herein can be prepared, in general, by reacting two equivalents of the base compound with the desired acid, in solution. Afterthe reaction is complete, the salts are crystallized from solution by the addition of an appropriate amount of solvent in which the salt is insoluble.
  • the pharmaceutically acceptable salt is a hydrochloride salt.
  • compositions comprising the aforementioned active compounds also are provided herein. These pharmaceutical formulations comprise active compounds as described herein, in a pharmaceutically acceptable carrier. Pharmaceutical formulations can be prepared for oral, intravenous, or aerosol administration as described in greater detail herein below. Also, the presently disclosed subject matter provides such active compounds that have been lyophilized and that can be reconstituted to form pharmaceutically acceptable formulations for administration, as by intravenous or intramuscular injection.
  • the therapeutically effective dosage of any specific active compound will vary somewhat from compound to compound, and patient to patient, and will depend upon the condition of the patient and the route of delivery. As a general proposition, a dosage from about 0.1 mg/kg to about 50 mg/kg will have therapeutic efficacy, with all weights being calculated based upon the weight of the active compound, including the cases where a salt is employed.
  • Toxicity concerns at the higher level can restrict intravenous dosages to a lower level such as up to about 10 mg/kg, with all weights being calculated based upon the weight of the active base, including the cases where a salt is employed.
  • a dosage from about 10 mg/kg to about 50 mg/kg can be employed for oral administration.
  • a dosage from about 0.5 mg/kg to 5 mg/kg can be employed for intramuscular injection.
  • dosages range from between 1 ⁇ mol/kg to 50 ⁇ mol/kg of the compound for intravenous or oral administration.
  • dosages range from between 22 ⁇ mol/kg and 33 ⁇ mol/kg of the compound for intravenous or oral administration.
  • compositions as described herein can be administered orally as a solid or as a liquid, or can be administered intramuscularly or intravenously as a solution, suspension, or emulsion. Alternatively, the compounds or salts can be administered by inhalation, intravenously or intramuscularly as a liposomal suspension.
  • the active compound or salt When administered through inhalation the active compound or salt should be in the form of a plurality of solid particles or droplets having, in some embodiments, a particle size from about 0.5 microns to about 5 microns, and in some embodiments, a particle size from about 1 micron to about 2 microns.
  • Pharmaceutical formulations suitable for intravenous or intramuscular injection are further embodiments provided herein.
  • the pharmaceutical formulations comprise a compound of Formula I described herein, a prodrug as described herein, or a pharmaceutically acceptable salt thereof, in any pharmaceutically acceptable carrier. If a solution is desired, water is the carrier of choice with respect to water-soluble compounds or salts.
  • an organic vehicle such as glycerol, propylene glycol, polyethylene glycol, or mixtures thereof, can be suitable.
  • the organic vehicle can contain a substantial amount of water.
  • the solution in either instance can then be sterilized in a suitable manner known to those in the art, and typically by filtration through a 0.22-micron filter. Subsequent to sterilization, the solution can be dispensed into appropriate receptacles, such as depyrogenated glass vials. Of course, the dispensing is preferably done by an aseptic method. Sterilized closures can then be placed on the vials and, if desired, the vial contents can be lyophilized.
  • the pharmaceutical formulations can contain other additives, such as pH-adjusting additives.
  • useful pH-adjusting agents include acids, such as hydrochloric acid, bases or buffers, such as sodium lactate, sodium acetate, sodium phosphate, sodium citrate, sodium borate, or sodium gluconate.
  • the formulations can contain anti-microbial preservatives.
  • Useful antimicrobial preservatives include methylparaben, propylparaben, and benzyl alcohol. The anti-microbial preservative is typically employed when the formulation is placed in a vial designed for multi-dose use.
  • the pharmaceutical formulations described herein can be lyophilized using techniques well known in the art.
  • an injectable, stable, sterile formulation comprising a compound of Formula I, or a salt thereof, in a unit dosage form in a sealed container.
  • the compound or salt is provided in the form of a lyophilizate, which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid formulation suitable for injection thereof into a subject.
  • the unit dosage form typically comprises from about 10 mg to about 10 grams of the compound salt.
  • a sufficient amount of emulsifying agent which is physiologically acceptable, can be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier.
  • phosphatidyl choline is phosphatidyl choline.
  • Other pharmaceutical formulations can be prepared from the water- insoluble compounds disclosed herein, or salts thereof, such as aqueous base emulsions. In such an instance, the formulation will contain a sufficient amount of pharmaceutically acceptable emulsifying agent to emulsify the desired amount of the compound or salt thereof.
  • Particularly useful emulsifying agents include phosphatidyl cholines, and lecithin.
  • Additional embodiments provided herein include liposomal formulations of the active compounds disclosed herein. The technology for forming liposomal suspensions is well known in the art.
  • the compound when the compound is an aqueous-soluble salt, using conventional liposome technology, the same can be incorporated into lipid vesicles. In such an instance, due to the water solubility of the active compound, the active compound will be substantially entrained within the hydrophilic center or core of the liposomes.
  • the lipid layer employed can be of any conventional composition and can either contain cholesterol or can be cholesterol-free.
  • the salt when the active compound of interest is water-insoluble, again employing conventional liposome formation technology, the salt can be substantially entrained within the hydrophobic lipid bilayer that forms the structure of the liposome. In either instance, the liposomes that are produced can be reduced in size, as through the use of standard sonication and homogenization techniques.
  • the liposomal formulations containing the active compounds disclosed herein can be lyophilized to produce a lyophilizate, which can be reconstituted with a pharmaceutically acceptable carrier, such as water, to regenerate a liposomal suspension.
  • Pharmaceutical formulations also are provided which are suitable for administration as an aerosol, by inhalation. These formulations comprise a solution or suspension of a desired compound described herein or a salt thereof, or a plurality of solid particles of the compound or salt.
  • the desired formulation can be placed in a small chamber and nebulized. Nebulization can be accomplished by compressed air or by ultrasonic energy to form a plurality of liquid droplets or solid particles comprising the compounds or salts.
  • the liquid droplets or solid particles have a particle size in the range of about 0.5 microns to about 10 microns. In some embodiments, the liquid droplets or solid particles have a particle size in the range of about 0.5 to about 5 microns.
  • the solid particles can be obtained by processing the solid compound or a salt thereof, in any appropriate manner known in the art, such as by micronization. In some embodiments, the size of the solid particles or droplets will be from about 1 micron to about 2 microns. In this respect, commercial nebulizers are available to achieve this purpose.
  • the compounds can be administered via an aerosol suspension of respirable particles in a manner set forth in U.S. Patent No. 5,628,984, the disclosure of which is incorporated herein by reference in its entirety.
  • the formulation will comprise a water-soluble active compound in a carrier that comprises water.
  • a surfactant can be present, which lowers the surface tension of the formulation sufficiently to result in the formation of droplets within the desired size range when subjected to nebulization.
  • water-soluble and water-insoluble active compounds are provided by the presently disclosed subject matter.
  • water-soluble is meant to define any composition that is soluble in water in an amount of about 50 mg/mL, or greater.
  • water-insoluble is meant to define any composition that has solubility in water of less than about 20 mg/mL.
  • the presently disclosed subject matter provides a pharmaceutical formulation comprising: (a) a pharmaceutically acceptable carrier; and (b) a compound of Formula I:
  • Ri and R 2 are each independently selected from the group consisting of H, alkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl;
  • m and n are integers from 0 to 3, provided that when m is zero, R ⁇ is an implied hydrogen, and when n is zero, R 2 is an implied hydrogen;
  • p and q are integers from 0 to 1 ;
  • a and A' are each independently selected from one of:
  • R 4 , R5, R ⁇ , R7, and R 8 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; or R 5 and R 6 together represent a C 2 to C 10 alkyl, hydroxyalkyl, or alkylene; or R 8 is Re — N R 10 wherein: Rg and R 10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R 11 is selected from the group consisting of H, alkyl, and aryl; or a pharmaceutically acceptable salt thereof.
  • X is CH 2 and Y is absent. In such embodiments, the fused-
  • R 4 and R 7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R 8 is selected from the group consisting of aryl and Re — N ⁇ R 10 wherein: R 9 and R-in are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R 11 is selected from the group consisting of H, alkyl, and aryl.
  • a and A' are in the 2- and 7-positions of the 9H-fluorene ring.
  • m and n are both zero and R is H.
  • R 4 is H and R 8 is phenyl.
  • R is H and R 8 is 2-pyridyl.
  • R 8 is
  • Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
  • a and A' are each independently wherein: p and q are each 1 ; R 4 and R 7 are each independently selected from the group consisting of H alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R 8 is selected from the group consisting of aryl and
  • Rg and R 10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
  • a and A' are in the 2- and 7-positions of the 9H-fluoren- 9-one ring.
  • m and n are both zero; and R 7 is H.
  • R 8 is R ⁇ — N R 10 wherein: Rg and R 10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R 11 is selected from the group consisting of H, alkyl, and aryl.
  • Rg and R1 0 are both H.
  • R 4 is H.
  • R is ethoxycarbonyl.
  • the fused-ring structure comprises 9,10-anthraquinone.
  • a and A' are each independently
  • R 4 and R 7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R 8 is selected from the group consisting of aryl and
  • Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
  • m and n are both zero and R is H.
  • R 8 is Re — wherein: Rg and R1 0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R11 is selected from the group consisting of H, alkyl, and aryl.
  • Rg and R 10 are both H.
  • R 4 is H.
  • X is N and Y is CH.
  • the fused-ring structure comprises acridine.
  • a and A' are each independently
  • R 4 and R 7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R 8 is selected from the group consisting of aryl and
  • Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R 11 is selected from the group consisting of H, alkyl, and aryl.
  • a and A' are in the 3- and 6-positions of the acridine ring.
  • m and n are both zero; and R is H.
  • R 8 is Re — N ⁇ R 10 wherein: R 9 and R 10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl.
  • Rg and R10 are both H.
  • R 4 is H.
  • the compound is selected from the group consisting of: 2,7-bis- guanidino-9H-fluorene; 2,7-bis-guanidinofluoren-9-one; 2,7-bis- guanidinoanthraquinone; 3,6-bis-guanidinoacridine; 2,7-bis-( ⁇ T- ethoxycarbonyl)guanidino-9H-fluorene; 2,7-bis( ⁇ /"- ethoxycarbonyl)guanidinofluoren-9-one; 2,7-bis( ⁇ /"-ethoxycarbonyl- ⁇ /'- methyl)guanidino-9/-/-fluorene; 2,7-bis( ⁇ /"-ethoxycarbonyl-A/'- isopropyl)guanidino-9/-/-fluorene; 2,7-bis( ⁇ /"-ethoxycarbonyl-A/'- isopropyl
  • Subjects with microbial infections can be treated by methods described herein. These infections can be caused by a variety of microbes, including fungi, algae, protozoa, bacteria, and viruses. Exemplary microbial infections that can be treated by the method of the presently disclosed subject matter include, but are not limited to, infections caused by Trypanosoma species (e.g., Trypanosoma brucei rhodesiense), Pneumocytsis carnii, Giardia lamblia,
  • compositions of Formula I are defined as having a structure as follows:
  • Ri and R 2 are each independently selected from the group consisting of H, alkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl;
  • m and n are integers from 0 to 3, provided that when m is zero, Ri is an implied hydrogen, and when n is zero, R 2 is an implied hydrogen;
  • p and q are integers from 0 to 1 ;
  • a and A' are each independently selected from one of: wherein: R 4 , R5.
  • R 7 . and R 8 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; or R 5 and R 6 together represent a C 2 to C 10 alkyl, hydroxyalkyl, or alkylene; or R 8 is Re — N R 10 wherein: Rg and R 10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R 11 is selected from the group consisting of H, alkyl, and aryl; or a pharmaceutically acceptable salt thereof.
  • X is CH 2 and Y is absent.
  • the fused-ring structure comprises 9/-/-fluorene.
  • a and A' are each independently
  • R 4 and R 7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R 8 is selected from the group consisting of aryl and 7 Re — N ⁇ R 10 wherein: R 9 and R ⁇ 0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
  • a and A' are in the 2- and 7-positions of the 9H-fluorene ring.
  • m and n are both zero and R 7 is H.
  • R 4 is H and R 8 is phenyl.
  • R 4 is H and R 8 is 2-pyridyl.
  • R 8 is Re — N R io wherein: R 9 and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
  • R 4 and Rg are each H.
  • R 4 is ethoxycarbonyl and R 9 is H.
  • R-io is H.
  • R ⁇ 0 is methyl.
  • R ⁇ 0 is isopropyl.
  • R ⁇ 0 is methoxyl.
  • R ⁇ 0 is iso-butoxyl.
  • the fused-ring structure comprises 9/-/-fluoren-9-one.
  • a and A' are each independently
  • R 4 and R 7 are each independently selected from the group consisting of H alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R 8 is selected from the group consisting of aryl and Re — N R M,O wherein: Rg and R ⁇ 0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
  • a and A' are in the 2- and 7-positions of the 9H-fluoren- 9-one ring.
  • m and n are both zero and R 7 is H.
  • R 8 is Re — N R ⁇ n wherein: Rg and R 10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
  • Rg and Rio are both H.
  • R 4 is H.
  • R 4 is ethoxycarbonyl.
  • the fused-ring structure comprises 9,10-anthraquinone.
  • a and A' are each independently
  • R 4 and R 7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R 8 is selected from the group consisting of aryl and
  • Rg and R-io are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, m and n are both zero and R 7 is H. In some embodiments, R 8 is Re — N ⁇ R 10 wherein: Rg and R 10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, Rg and R ⁇ 0 are both H. In some embodiments, R 4 is H. In some embodiments of the method of treating a microbial infection by administering to a subject in need of treatment thereof a compound of
  • X is N and Y is CH.
  • the fused-ring structure comprises acridine.
  • a and A' are each independently
  • R 4 and R are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R 8 is selected from the group consisting of aryl and R 9 — N ⁇ R 10 wherein: R 9 and R ⁇ 0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
  • a and A' are in the 3- and 6-positions of the acridine ring.
  • m and n are both zero and R is H.
  • R 8 is
  • Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, Rg and Rio are both H. In some embodiments, R is H.
  • the method comprises a compound of Formula I selected from the group consisting of: 2,7-bis-guanidino-9/- -fluorene; 2,7-bis-guanidinofluoren-9- one; 2,7-bis-guanidinoanthraquinone; 3,6-bis-guanidinoacridine; 2,7-bis-( ⁇ /"- ethoxycarbonyl)guanidino-9H-fluorene; 2,7-bis( ⁇ /"- ethoxycarbonyl)guanidinofluoren-9-one; 2,7-bis( ⁇ /"-ethoxycarbonyl- ⁇ /- methyl)guanidino-9H-fluorene; 2,7-bis(/V"-ethoxycarbonyl-/V- isopropyl)guanidino-9H-fluorene; 2,7-bis( ⁇ /"-
  • the compound of Formula I is administered in the form of a pharmaceutically acceptable salt.
  • the pharmaceutically acceptable salt is a hydrochloride salt.
  • the microbial infection is selected from one of a Trypanosoma brucei rhodesiense infection and a Plasmodium falciparum infection.
  • the subject treated in the presently disclosed subject matter in its many embodiments is desirably a human subject, although it is to be understood the methods described herein are effective with respect to all vertebrate species, which are intended to be included in the term "subject".
  • the methods described herein are particularly useful in the treatment and/or prevention of infectious diseases in warm-blooded vertebrates. Thus, the methods can be used as treatment for mammals and birds.
  • mammals such as humans, as well as those mammals of importance due to being endangered (such as Siberian tigers), of economical importance (animals raised on farms for consumption by humans) and/or social importance (animals kept as pets or in zoos) to humans, for instance, carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and wild boars), ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses.
  • carnivores other than humans such as cats and dogs
  • swine pigs, hogs, and wild boars
  • ruminants such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels
  • kits for treating birds including the treatment of those kinds of birds that are endangered, kept in zoos, as well as fowl, and more particularly domesticated fowl, i.e., poultry, such as turkeys, chickens, ducks, geese, guinea fowl, and the like, as they also are of economical importance to humans.
  • embodiments of the methods described herein include the treatment of livestock, including, but not limited to, domesticated swine (pigs and hogs), ruminants, horses, poultry, and the like.
  • 2,7-Bis( ⁇ /"-ethoxycarbonylthiourea)-9W-fluorene (6a).
  • Two compounds (8a and 5b) show IC-50 values versus Trypanosoma brucei rhodesiense (T.b.r.) at 13 nM or less.
  • Two compounds (5a and 8a) show IC-50 values versus Plasmodium falciparum (p.f.) at 10 nM or less.
  • Compounds 8a and 8b give 3/4 and 4/4 cures versus the virulent STIP900 strain of T.b.r. in a mouse model. Prodrugs of these compounds hold promise as an oral treatment of both malaria and human African trypanosomiasis.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Novel fused ring dicationic anti-protozoan compounds. Representative protozoan species include but are not limited to Trypanosoma brucei rhodesiense (T.b.r) and Plasmodium faciparum. Prodrugs of these compounds can be used as an oral treatment for malaria and human African trypanosomiasis.

Description

DESCRIPTION FUSED RING DICATIONIC ANTI-PROTOZOAN AGENTS AND THEIR PRODRUGS
CROSS REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Patent Application Serial No. 60/525,018, filed November 24, 2003, the disclosure of which is incorporated herein by reference in its entirety.
TECHNICAL FIELD The presently disclosed subject matter relates to methods of combating microbial infections with dicationic compounds. More particularly, the presently disclosed subject matter relates to methods of combating microbial infections with fused ring dicationic compounds, and to the novel compounds themselves.
ABBREVIATIONS δ = chemical shift Ac = acetyl AcO = acetoxyl AcOH = acetic acid Ac20 = acetic anhydride Am = amidine AmOH = amidoxime BOC = f-butoxycarbonyl Bu = butyl °C = degrees Celsius calcd = calculated cm = centimeters dec = decomposition point DIBAL = diisobutylaluminium hydride DMF = dimethylformamide DMSO = dimethylsulfoxide D20 = deuterium oxide EtOAc = ethyl acetate
EtOH = ethanol
FAB = fast atom bombardment g = grams h = hours
HCI = hydrogen chloride
HPLC = high-pressure liquid chromatography
Hz = hertz kg = kilograms
KO-f-Bu = potassium terf-butoxide
L. d. = Leishmania donovani
M = molar
Me = methyl
MeO = methoxyl
MHz = megahertz mL = milliliters mm = millimeters mM = millimolar m.p. = melting point
MS = mass spectroscopy
Na2C03 = sodium carbonate
Na2SO4 = sodium sulfate
NBS = Λ/-bromosuccinimide
NH2OH»HCI = hydroxylamine hydrochlonde
NMR = nuclear magnetic resonance
P = para
Pd-C = 10% palladium on carbon
P. f. = Plasmodium falciparum psi = pounds per square inch spp. = species
T. br. = Trypanosoma brucei rhodesiense
THF = tetrahydrofuran
TLC = thin-layer chromatography TMS = trimethylsilyl UV = ultraviolet
BACKGROUND The incidence of microbial infections (e.g., mycobactehal, fungal, and protozoal infections) in the immunocompromised population has significantly increased over the past several years. In particular, Candida species, especially Candida albicans, are often significant pathogens in patients infected with human immunodeficiency virus (HIV). Another pathogen, Pneumocystis carinii, causes a form of pneumonia (PCP) that is believed to be one of the leading causes of death in patients suffering from AIDS. Further, Human African trypanosomiasis (HAT) has reemerged as a threat to over 60 million people. Current estimates are that between 350,000 and 450,000 people are infected. Other severe and life-threatening microbial infections are caused by Mycobacterium tuberculosis, Aspergillus spp., Cryptospo dium parvum, Giardia lamblia, Plasmodium spp., Toxoplasma gondii, Fusarium solan i, and Cryptococcus neoformans. The antimicrobial properties of dicationic molecules have been studied since the 1930's. Compounds of this type have typically utilized amidine groups as the cationic moieties, and their activities against a number of pathogens including Cryptosporidium parvum, Giardia lamblia, Leishmania spp., Plasmodium spp., Pneumocystis carinii, Toxoplasma gondii, Trypanosoma spp., Candida albicans, Aspergillus spp. and Cryptococcus neoformans have been reported. See, e.g., King, H. et al.. Ann. Trop. Med. Parasitol. 1938, 32, 177-192; Blaqbum, B. L. et al.. Antimicrob. Agents
Chemother. 1991 , 35, 1520-1523; Bell, C. A. et al.. Antimicrob. Agents Chemother. 1991 , 35, 1099-1107; Bell. C. A. et al.. Antimicrob. Agents Chemother. 1990, 34, 1381-1386; Kirk. R. et al.. Ann. Trop. Med. Parastiol. 1940, 34, 181-197; Fulton. J. D. Ann. Trop. Med. Parasitol. 1940, 34, 53-66; Ivadv. V. G. et al.. Monatschr. Kinderheilkd. 1958, 106, 10-14; Bovkin. P. W. et aL, J. Med. Chem. 1995, 38, 912-916; Bovkin. P. W. et al.. J. Med. Chem. 1998, 41 , 124-129; Francesconi. I. et aL J. Med. Chem. 1999, 42, 2260-2265; Lindsay. P. S. et al.. Antimicrob. Agents Chemother. 1991 , 35, 1914-1916; Lourie. E. M. et a Ann. Trop. Med. Parasitol. 1939, 33, 289-304; Lourie. E. M. et al., Ann. Trop. Med. Parasitol. 1939, 33, 305-312; Das. B. P. et al.. J Med.
Chem. 1976, 20, 531-536; Del Poeta. M. et al.. J. Antimicrob. Chemother.
1999, 44, 223-228; Del Poeta. M. et al.. Antimicrob. Agents Chemother. 1998, 42, 2495-2502; Del Poeta, M. et al.. Antimicrob. Agents Chemother. 1998, 42,
2503-2510. Despite the broad range of activity exhibited by diamidines, only one compound of this chemical type, pentamidine, has seen significant clinical use.
Pentamidine has been used clinically against African trypanosomiasis, antimony-resistant leishmaniasis, and P. carinii pneumonia. See, e.g., Apted.
F. I. C.. Pharmacol. Ther. 1980, 11 , 391-413; Brvceson. A. P. M. et al.. Trans.
Roy. Soc. Trop. Med. Hyg. 1985, 79, 705-714; Hughes. W.T. et a Antimicrob.
Agents Chemother. 1974, 5, 289-293. Thus, there is a need for compounds having antimicrobial activity, whether against the representative pathogens referenced above or against other pathogens. More particularly, there is a need for a compound having activity in the treatment of human African trypanosomiasis, an infectious disease for which oral treatment in its second stage is not currently available. SUMMARY The presently disclosed subject matter describes a compound of Formula I:
Figure imgf000005_0001
wherein: X and Y are each independently selected from the group consisting of CH, CH2, N, C=0, O, S, and NR3> wherein R3 is selected from the group consisting of H, alkyl, aryl, alkoxyl, and aryloxyl, and Y can be present or absent; Ri and R2 are each independently selected from the group consisting of H, alkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl; m and n are integers from 0 to 3, provided that when m is zero, Ri is an implied hydrogen, and when n is zero, R2 is an implied hydrogen; p and q are integers from 0 to 1 ; A and A' are each independently selected from one of:
Figure imgf000006_0001
wherein: R4, R5, Re, R7, and R& are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; or R5 and Re together represent a C2 to C10 alkyl, hydroxyalkyl, or alkylene; or R8 is Re — N R, wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R11 is selected from the group consisting of H, alkyl, and aryl. In some embodiments, the presently disclosed subject matter relates to a pharmaceutical formulation comprising a compound of Formula I in a pharmaceutically acceptable carrier. In some embodiments, the presently disclosed subject matter relates to a method of treating a microbial infection, comprising administering an effective amount of a compound of Formula I to a subject in need thereof. In some embodiments, the presently disclosed subject matter relates to the use of an active compound as described hereinabove (i.e., a compound of
Formula l)forthe preparation of a medicament for treating a microbial infection. Accordingly, in some embodiments, the presently disclosed subject matter provides compounds that are useful in the treatment of microbial infections. In some embodiments, the presently disclosed subject matter provides pharmaceutical formulations for use in the treatment of microbial infections. In some embodiments, the presently disclosed subject matter provides methods for treating microbial infections. Certain embodiments of the presently disclosed subject matter having been stated hereinabove, which are addressed in whole or in part by the presently disclosed subject matter, other embodiments will become evident as the description proceeds when taken in connection with the accompanying
Examples as best described herein below.
PETAILEP PESCRIPTION The presently disclosed subject matter will now be described more fully hereinafter with reference to the accompanying Examples, in which representative embodiments are shown. The presently disclosed subject matter can, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the embodiments to those skilled in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this presently described subject matter belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. Throughout the specification and claims, a given chemical formula or name shall encompass all optical and stereoisomers, as well as racemic mixtures where such isomers and mixtures exist.
L Pefinitions As used herein the term "alkyl" refers to C1-20 inclusive, linear (i.e., "straight-chain"), branched, or cyclic, saturated or at least partially and in some cases fully unsaturated (i.e., alkenyl and alkynyl) hydrocarbon chains, including for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, and allenyl groups. "Branched" refers to an alkyl group in which a lower alkyl group, such as methyl, ethyl or propyl, is attached to a linear alkyl chain. "Lower alkyl" refers to an alkyl group having 1 to about 8 carbon atoms (i.e., a C-i-β alkyl), i.e., 1 , 2, 3, 4, 5, 6, 7, or 8 carbon atoms. "Higher alkyl" refers to an alkyl group having about 10 to about
20 carbon atoms, i.e., 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms (i.e., a Cι0-2o alkyl). In certain embodiments, "alkyl" refers, in particular, to C-ι-8 straight-chain alkyls. In other embodiments, "alkyl" refers, in particular, to Ci-8 branched-chain alkyls. Alkyl groups can be optionally substituted with one or more alkyl group substituents, which can be the same or different. The term "alkyl group substituent" includes but is not limited to alkyl, halo, arylamino, acyl, hydroxyl, aryloxyl, alkoxyl, alkylthio, arylthio, aralkyloxyl, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl. There can be optionally inserted along the alkyl chain one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms, wherein the nitrogen substituent is hydrogen, lower alkyl (also referred to herein as "alkylaminoalkyl"), or aryl. The term "aryl" is used herein to refer to an aromatic substituent that can be a single aromatic ring, or multiple aromatic rings that are fused together, linked covalently, or linked to a common group such as a methylene or ethylene moiety. The common linking group also can be a carbonyl as in benzophenone or oxygen as in diphenylether or nitrogen as in diphenylamine. The term "aryl" specifically encompasses heterocyclic aromatic compounds. The aromatic ring(s) can comprise phenyl, naphthyl, biphenyl, diphenylether, diphenylamine and benzophenone, among others. In some embodiments, the term "aryl" means a cyclic aromatic comprising from about 5 to about 10 carbon atoms, i.e., 5, 6, 7, 8, 9, or 10 carbon atoms, and including 5- and 6-membered hydrocarbon and heterocyclic aromatic rings. The aryl group can be optionally substituted with one or more aryl group substituents which can be the same or different, wherein "aryl group substituent" includes alkyl, aryl, aralkyl, hydroxyl, alkoxyl, aryloxyl, aralkyloxyl, carboxyl, acyl, halo, nitro, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acyloxyl, acylamino, aroylamino, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylthio, alkylthio, alkylene, and -NR'R", wherein R' and R" can be each independently hydrogen, alkyl, aryl, and aralkyl. Specific examples of aryl groups include but are not limited to cyclopentadienyl, phenyl, furan, thiophene, pyrrole, pyran, pyridine, imidazole, benzimidazole, isothiazole, isoxazole, pyrazole, pyrazine, triazine, pyrimidine, quinoline, isoquinoline, indole, carbazole, and the like. A dashed line representing a bond in an aryl group indicates that the bond is either present or absent depending on the number of atoms comprising the aromatic ring and, in the case of a heterocyclic aromatic ring, the identity of the heteroatom. When a named atom of an aromatic ring or a heterocyclic aromatic ring is defined as being "absent," the named atom is replaced by a direct bond. As used herein, the terms "substituted alkyl" and "substituted aryl" include alkyl and aryl groups, as defined herein, in which one or more atoms or functional groups of the aryl or alkyl group are replaced with another atom or functional group, including for example, halogen, aryl, alkyl, alkoxyl, hydroxyl, nitro, amino, alkylamino, dialkylamino, sulfate, and mercapto. As used herein, the term "acyl" refers to an organic acid group wherein the -OH of the carboxyl group has been replaced with another substituent (i.e., as represented by RCO — , wherein R is an alkyl or an aryl group as defined herein). As such, the term "acyl" specifically includes arylacyl groups. Specific examples of acyl groups include acetyl and benzoyl. "Cyclic" and "cycloalkyl" refer to a non-aromatic mono- or multi-cyclic ring system of about 3 to about 10 carbon atoms, i.e., 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. The cycloalkyl group can be optionally partially unsaturated. The cycloalkyl group can be also optionally substituted with an alkyl group substituent as defined herein, oxo, and/or alkylene. There can be optionally inserted along the cyclic alkyl chain one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms, wherein the nitrogen substituent is hydrogen, lower alkyl, or aryl, thus providing a heterocyclic group. Representative monocyclic cycloalkyl rings include cyclopentyl, cyclohexyl, and cycloheptyl. Multicyclic cycloalkyl rings include adamantyl, octahydronaphthyl, decalin, camphor, camphane, and noradamantyl. "Alkoxyl" or "alkoxyalkyl" refer to an alkyl-O- group wherein alkyl is as previously described. The term "alkoxyl" as used herein can refer to Cι-2o inclusive, linear, branched, or cyclic, saturated or unsaturated oxo-hydrocarbon chains, including, for example, methoxyl, ethoxyl, propoxyl, isopropoxyl, butoxyl, f-butoxyl, and pentoxyl. "Aryloxyl" refers to an aryl-O- group wherein the aryl group is as previously described. The term "aryloxyl" as used herein can refer to phenyloxyl or hexyloxyl, and alkyl, halo, or alkoxyl substituted phenyloxyl or hexyloxyl. "Aralkyl" refers to an aryl-alkyl- group wherein aryl and alkyl are as previously described. Exemplary aralkyl groups include benzyl, phenylethyl, and naphthylmethyl. "Aralkyloxyl" refers to an aralkyl-O- group wherein the aralkyl group is as previously described. An exemplary aralkyloxyl group is benzyloxyl. "Pialkylamino" refers to an -NRR' group wherein each of R and R' is independently an alkyl group as previously described. Exemplary alkylamino groups include ethylmethylamino, dimethylamino, and diethylamino. "Alkoxycarbonyl" refers to an alkyl-0-C(=0)- group. Exemplary alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, butyloxycarbonyl, and f-butyloxycarbonyl. An alkoxycarbonyl group can be further represented by the following structural formula: O II — C-O-R wherein the "R" group represents an alkyl group as defined hereinabove. An alkoxycarbonyl group also can be referred to as an "alkyl ester" group. In some embodiments of the presently disclosed subject matter, R is an ethyl group and the alkoxycarbonyl group comprises the following formula: O II — C-0-CH2CH3
"Aryloxycarbonyl" refers to an aryl-0-C(=0)- group. Exemplary aryloxycarbonyl groups include phenoxy- and naphthoxy-carbonyl. "Aralkoxycarbonyl" refers to an aralkyl-0-C(=0)- group. An exemplary aralkoxycarbonyl group is benzyloxycarbonyl. "Carbamoyl" refers to an H2N-C(=0)- group. "Alkylcarbamoyl" refers to a R'RN-C(=0)- group wherein one of R and R' is hydrogen and the other of R and R' is alkyl as previously described. "Pialkylcarbamoyl" refers to R'RN-C(=0)- group wherein each of R and R' is independently alkyl as previously described. "Acyloxyl" refers to an acyl-O- group wherein acyl is as previously described. "Acylamino" refers to an acyl-NH- group wherein acyl is as previously described. "Aroylamino" refers to an aroyl-NH- group wherein aroyl is as previously described. "Alkylene" refers to a straight or branched bivalent aliphatic hydrocarbon group having from 1 to about 20 carbon atoms, i.e., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. The alkylene group can be straight, branched or cyclic. The alkylene group can be also optionally unsaturated and/or substituted with one or more "alkyl group substituents." There can be optionally inserted along the alkylene group one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms (also referred to herein as "alkylaminoalkyl"), wherein the nitrogen substituent is alkyl as previously described. Exemplary alkylene groups include methylene (-CH2-); ethylene
(-CH2-CH2-); propylene (-(CH2)3-); cyclohexylene (-C6Hι0-); -CH=CH— CH=CH-; -CH=CH-CH2-; -(CH2)q-N(RHCH2)r-, wherein each of q and r is independently an integer from 0 to about 20, i.e., 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20, and R is hydrogen or lower alkyl; methylenedioxyl (-0-CH2-0-); and ethylenedioxyl (-0-(CH2)2-0-). An alkylene group can have about 2 to about 3 carbon atoms and can further have
6-20 carbons. The term "amino" refers to the -NH2 group. The term "carbonyl" refers to the -(C=0)- group. The term "carboxyl" refers to the -C(=0)OH group. The terms "halo", "halide", or "halogen" as used herein refer to fluoro, chloro, bromo, and iodo groups. The term "hydroxyl" refers to the -OH group. The term "hydroxyalkyl" refers to an alkyl group substituted with an -OH group. The term "mercapto" refers to the -SH group. The term "oxo" refers to a compound described previously herein wherein a carbon atom is replaced by an oxygen atom. The term "nitro" refers to the -N02 group. The term "thio" refers to a compound described previously herein wherein a carbon or oxygen atom is replaced by a sulfur atom. The term "sulfate" refers to the -S04 group. When the term "independently selected" is used, the substituents being referred to (i.e., R groups, such as groups Ri and R2, or groups X and Y), can be identical or different. For example, both Ri and R2 can be substituted alkyls, or Ri can be hydrogen and R2 can be a substituted alkyl, and the like. A named "R", "R'," "X," "Y," T", "A," "A"', "B," "L," or "Z" group generally will have the structure that is recognized in the art as corresponding to a group having that name, unless specified otherwise herein. For the purposes of illustration, certain representative "R," "X," "Y", and "A" groups as set forth above are defined below. These definitions are intended to supplement and illustrate, not preclude, the definitions that would be apparent to one of ordinary skill in the art upon review of the present disclosure. \\_ Novel Compounds ___ Compounds of Formula I In some embodiments, the presently disclosed subject matter provides a compound of Formula I:
Figure imgf000013_0001
wherein: X and Y are each independently selected from the group consisting of CH, CH2, N, CO, O, S, and NR3, wherein R3 is selected from the group consisting of H, alkyl, aryl, alkoxyl, and aryloxyl, and Y can be present or absent; R-i and R2are each independently selected from the group consisting of H, alkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl; m and n are integers from 0 to 3, provided that when m is zero, Ri is an implied hydrogen, and when n is zero, R2 is an implied hydrogen; p and q are integers from 0 to 1 ; A and A' are each independently selected from one of:
Figure imgf000013_0002
wherein: R4, R5, Re, R7, and R8 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; or R5 and R& together represent a C2 to C10 alkyl, hydroxyalkyl, or alkylene; or Re is R9 — N \ R 10 wherein: R9 and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R11 is selected from the group consisting of H, alkyl, and aryl. In some embodiments of the compound of Formula I, X is CH2 and Y is absent. In such embodiments, the fused-ring structure comprises 9H-fluorene.
In some embodiments, A and A' are each independently
Figure imgf000014_0001
wherein: p and q are each 1 ; R and R are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and Re is selected from the group consisting of aryl and
Figure imgf000014_0002
wherein: R9 and Rι0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R11 is selected from the group consisting of H, alkyl, and aryl. In some embodiments, A and A' are in the 2- and 7-positions of the 9H-fluorene ring. In some embodiments, m and n are both zero and R7 is H. In some embodiments, R4 is H and Re is phenyl. In some embodiments, R4 is H and R8 is 2-pyridyl. In some embodiments, R8 is
Figure imgf000015_0001
wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl.
In some embodiments, R4 and Rg are each H. In some embodiments, R4 is ethoxycarbonyl and R9 is H. In some embodiments, Rio is H. In some embodiments, R10 is methyl. In some embodiments, R-|0 is isopropyl. In some embodiments, R-io is methoxyl. In some embodiments, Rio is iso-butoxyl. In some embodiments of the compound of Formula I, X is C=0 and Y is absent. In such embodiments, the fused-ring structure comprises 9H-fluoren-9- one. In some embodiments, A and A' are each independently
Figure imgf000015_0002
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and R9 — N \ R 10 wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -OR-π; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl. In some embodiments, A and A' are in the 2- and 7-positions of the 9H-fluoren- 9-one ring. In some embodiments, m and n are both zero and R is H. In some embodiments, R8 is
Figure imgf000016_0001
wherein: Rg and Rι0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R11 is selected from the group consisting of H, alkyl, and aryl. In some embodiments, Rg and Rio are both H. In some embodiments, R4 is H. In some embodiments, R4 is ethoxycarbonyl. In some embodiments of the compound of Formula I, X and Y are both
C=0. In such embodiments, the fused-ring structure comprises 9,10- anthraquinone. In some embodiments, A and A' are each independently
Figure imgf000016_0002
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and R9 — N \ Rl° wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
In some embodiments, m and n are both zero and R7 is H. In some embodiments, R8 is
—
Figure imgf000017_0001
wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R11 is selected from the group consisting of H, alkyl, and aryl.
In some embodiments, Rg and Rio are both H. In some embodiments, R is H. In some embodiments of the compounds of Formula I, X is N and Y is CH. In such embodiments, the fused-ring structure comprises acridine. In some embodiments, A and A' are each independently
Figure imgf000017_0002
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and Re — N \ R 10 wherein: Rg and Rι0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl. In some embodiments, A and A' are in the 3- and 6-positions of the acridine ring. In some embodiments, m and n are both zero and R is H. In some embodiments, R8 is
—
Figure imgf000018_0001
wherein: Rg and R-io are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
In some embodiments, Rg and R-ι0 are both H. In some embodiments, R4 is H. In some embodiments of the compound of Formula I, the compound is selected from the group consisting of: 2,7-bis-guanidino-9H-fluorene; 2,7-bis- guanidinofluoren-9-one; 2,7-bis-guanidinoanthraquinone; 3,6-bis- guanidinoacridine; 2,7-bis-(Λ/"-ethoxycarbonyl)guanidino-9H-fluorene; 2,7- bis(A/"-ethoxycarbonyl)guanidinofluoren-9-one; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/- methyl)guanidino-9H-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/- isopropyl)guanidino-9/-/-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/'- methoxy)guanidino-9H-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/- isobutoxy)guanidine-9H-fluorene; 2,7-bis(Λ/-methyl)guanidino-9H-fluorene; 2,7- bis(Λ/'-iso-propyl)guanidino-9/-/-fluorene; 2,7-bis(Λ/'-methoxy)guanidino-9H- fluorene; 2,7-bis(Λ/-isobutoxy)guanidine-9H-fluorene; 2,7- bis[(phenylimino)amino)]-9/-/-fluorene; and 2,7-bis[(2-pyridylimino)amino)-9/-/- fluorene. In some embodiments, the compound of Formula I comprises a pharmaceutically acceptable salt. In some embodiments, the salt is a hydrochloride salt. B. Prodrugs In representative embodiments, compounds disclosed herein are prodrugs. A prodrug means a compound that, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this presently disclosed subject matter or an inhibitorily active metabolite or residue thereof. Prodrugs can increase the bioavailability of the compounds of the presently disclosed subject matter when such compounds are administered to a subject (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or can enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to a metabolite species, for example. A number of the compounds (e.g., compounds 7a, 7b, 7c, 7d, 8c, and 10) discussed in Example 2 are prodrugs. C. Pharmaceutically Acceptable Salts Additionally, the active compounds of the presently disclosed subject matter can be administered as pharmaceutically acceptable salts. Such salts include the gluconate, lactate, acetate, tartarate, citrate, phosphate, borate, nitrate, sulfate, and hydrochloride salts. The salts of the compounds described herein can be prepared, in general, by reacting two equivalents of the base compound with the desired acid, in solution. Afterthe reaction is complete, the salts are crystallized from solution by the addition of an appropriate amount of solvent in which the salt is insoluble. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt. III. Pharmaceutical Formulations The compounds of Formula I, the pharmaceutically acceptable salts thereof, prodrugs corresponding to compounds of Formula I, and the pharmaceutically acceptable salts thereof, are all referred to herein as "active compounds." Pharmaceutical formulations comprising the aforementioned active compounds also are provided herein. These pharmaceutical formulations comprise active compounds as described herein, in a pharmaceutically acceptable carrier. Pharmaceutical formulations can be prepared for oral, intravenous, or aerosol administration as described in greater detail herein below. Also, the presently disclosed subject matter provides such active compounds that have been lyophilized and that can be reconstituted to form pharmaceutically acceptable formulations for administration, as by intravenous or intramuscular injection. The therapeutically effective dosage of any specific active compound, the use of which is in the scope of embodiments described herein, will vary somewhat from compound to compound, and patient to patient, and will depend upon the condition of the patient and the route of delivery. As a general proposition, a dosage from about 0.1 mg/kg to about 50 mg/kg will have therapeutic efficacy, with all weights being calculated based upon the weight of the active compound, including the cases where a salt is employed.
Toxicity concerns at the higher level can restrict intravenous dosages to a lower level such as up to about 10 mg/kg, with all weights being calculated based upon the weight of the active base, including the cases where a salt is employed. A dosage from about 10 mg/kg to about 50 mg/kg can be employed for oral administration. Typically, a dosage from about 0.5 mg/kg to 5 mg/kg can be employed for intramuscular injection. In some embodiments, dosages range from between 1 μmol/kg to 50 μmol/kg of the compound for intravenous or oral administration. In some embodiments, dosages range from between 22 μmol/kg and 33 μmol/kg of the compound for intravenous or oral administration. The duration of the treatment typically is once per day for a period of two to three weeks or until the condition is essentially controlled. Lower doses given less frequently can be used prophylactically to prevent or reduce the incidence of recurrence of the infection. In accordance with the presently disclosed methods, pharmaceutically active compounds as described herein can be administered orally as a solid or as a liquid, or can be administered intramuscularly or intravenously as a solution, suspension, or emulsion. Alternatively, the compounds or salts can be administered by inhalation, intravenously or intramuscularly as a liposomal suspension. When administered through inhalation the active compound or salt should be in the form of a plurality of solid particles or droplets having, in some embodiments, a particle size from about 0.5 microns to about 5 microns, and in some embodiments, a particle size from about 1 micron to about 2 microns. Pharmaceutical formulations suitable for intravenous or intramuscular injection are further embodiments provided herein. The pharmaceutical formulations comprise a compound of Formula I described herein, a prodrug as described herein, or a pharmaceutically acceptable salt thereof, in any pharmaceutically acceptable carrier. If a solution is desired, water is the carrier of choice with respect to water-soluble compounds or salts. With respect to the water-soluble compounds or salts, an organic vehicle, such as glycerol, propylene glycol, polyethylene glycol, or mixtures thereof, can be suitable. In the latter instance, the organic vehicle can contain a substantial amount of water. The solution in either instance can then be sterilized in a suitable manner known to those in the art, and typically by filtration through a 0.22-micron filter. Subsequent to sterilization, the solution can be dispensed into appropriate receptacles, such as depyrogenated glass vials. Of course, the dispensing is preferably done by an aseptic method. Sterilized closures can then be placed on the vials and, if desired, the vial contents can be lyophilized. In addition to compounds of Formula I or their salts or prodrugs, the pharmaceutical formulations can contain other additives, such as pH-adjusting additives. In particular, useful pH-adjusting agents include acids, such as hydrochloric acid, bases or buffers, such as sodium lactate, sodium acetate, sodium phosphate, sodium citrate, sodium borate, or sodium gluconate. Further, the formulations can contain anti-microbial preservatives. Useful antimicrobial preservatives include methylparaben, propylparaben, and benzyl alcohol. The anti-microbial preservative is typically employed when the formulation is placed in a vial designed for multi-dose use. The pharmaceutical formulations described herein can be lyophilized using techniques well known in the art. In some embodiments of the subject matter described herein, there is provided an injectable, stable, sterile formulation comprising a compound of Formula I, or a salt thereof, in a unit dosage form in a sealed container. The compound or salt is provided in the form of a lyophilizate, which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid formulation suitable for injection thereof into a subject. The unit dosage form typically comprises from about 10 mg to about 10 grams of the compound salt. When the compound or salt is substantially water-insoluble, a sufficient amount of emulsifying agent, which is physiologically acceptable, can be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier. One such useful emulsifying agent is phosphatidyl choline. Other pharmaceutical formulations can be prepared from the water- insoluble compounds disclosed herein, or salts thereof, such as aqueous base emulsions. In such an instance, the formulation will contain a sufficient amount of pharmaceutically acceptable emulsifying agent to emulsify the desired amount of the compound or salt thereof. Particularly useful emulsifying agents include phosphatidyl cholines, and lecithin. Additional embodiments provided herein include liposomal formulations of the active compounds disclosed herein. The technology for forming liposomal suspensions is well known in the art. When the compound is an aqueous-soluble salt, using conventional liposome technology, the same can be incorporated into lipid vesicles. In such an instance, due to the water solubility of the active compound, the active compound will be substantially entrained within the hydrophilic center or core of the liposomes. The lipid layer employed can be of any conventional composition and can either contain cholesterol or can be cholesterol-free. When the active compound of interest is water-insoluble, again employing conventional liposome formation technology, the salt can be substantially entrained within the hydrophobic lipid bilayer that forms the structure of the liposome. In either instance, the liposomes that are produced can be reduced in size, as through the use of standard sonication and homogenization techniques. The liposomal formulations containing the active compounds disclosed herein can be lyophilized to produce a lyophilizate, which can be reconstituted with a pharmaceutically acceptable carrier, such as water, to regenerate a liposomal suspension. Pharmaceutical formulations also are provided which are suitable for administration as an aerosol, by inhalation. These formulations comprise a solution or suspension of a desired compound described herein or a salt thereof, or a plurality of solid particles of the compound or salt. The desired formulation can be placed in a small chamber and nebulized. Nebulization can be accomplished by compressed air or by ultrasonic energy to form a plurality of liquid droplets or solid particles comprising the compounds or salts. In some embodiments, the liquid droplets or solid particles have a particle size in the range of about 0.5 microns to about 10 microns. In some embodiments, the liquid droplets or solid particles have a particle size in the range of about 0.5 to about 5 microns. The solid particles can be obtained by processing the solid compound or a salt thereof, in any appropriate manner known in the art, such as by micronization. In some embodiments, the size of the solid particles or droplets will be from about 1 micron to about 2 microns. In this respect, commercial nebulizers are available to achieve this purpose. The compounds can be administered via an aerosol suspension of respirable particles in a manner set forth in U.S. Patent No. 5,628,984, the disclosure of which is incorporated herein by reference in its entirety. When the pharmaceutical formulation suitable for administration as an aerosol is in the form of a liquid, the formulation will comprise a water-soluble active compound in a carrier that comprises water. A surfactant can be present, which lowers the surface tension of the formulation sufficiently to result in the formation of droplets within the desired size range when subjected to nebulization. As indicated, both water-soluble and water-insoluble active compounds are provided by the presently disclosed subject matter. As used in the presently disclosed subject matter, the term "water-soluble" is meant to define any composition that is soluble in water in an amount of about 50 mg/mL, or greater. Also, as used in the presently disclosed subject matter, the term "water-insoluble" is meant to define any composition that has solubility in water of less than about 20 mg/mL. For certain applications, water-soluble compounds or salts can be desirable whereas for other applications water- insoluble compounds or salts likewise can be desirable. Accordingly, in some embodiments, the presently disclosed subject matter provides a pharmaceutical formulation comprising: (a) a pharmaceutically acceptable carrier; and (b) a compound of Formula I:
Figure imgf000024_0001
wherein: X and Y are each independently selected from the group consisting of CH, CH2, N, C=0, O, S, and NR3, wherein R3 is selected from the group consisting of H, alkyl, aryl, alkoxyl, and aryloxyl, and Y can be present or absent; Ri and R2 are each independently selected from the group consisting of H, alkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl; m and n are integers from 0 to 3, provided that when m is zero, R^ is an implied hydrogen, and when n is zero, R2 is an implied hydrogen; p and q are integers from 0 to 1 ; A and A' are each independently selected from one of:
Figure imgf000024_0002
wherein: R4, R5, Rβ, R7, and R8 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; or R5 and R6 together represent a C2 to C10 alkyl, hydroxyalkyl, or alkylene; or R8 is Re — N R 10 wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl; or a pharmaceutically acceptable salt thereof. In some embodiments of the pharmaceutical formulation of a compound of Formula I, X is CH2 and Y is absent. In such embodiments, the fused-ring structure comprises 9/- -fluorene. In some embodiments, A and A' are each independently
Figure imgf000025_0001
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and Re — N \ R 10 wherein: R9 and R-in are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R11 is selected from the group consisting of H, alkyl, and aryl. In some embodiments, A and A' are in the 2- and 7-positions of the 9H-fluorene ring. In some embodiments, m and n are both zero and R is H. In some embodiments, R4 is H and R8 is phenyl. In some embodiments, R is H and R8 is 2-pyridyl. In some embodiments, R8 is
Figure imgf000026_0001
wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
In some embodiments, R4 and Rg are each H. In some embodiments, R4 is ethoxycarbonyl and Rg is H. In some embodiments, R10 is H. In some embodiments, Rio is methyl. In some embodiments, Rio is isopropyl. In some embodiments, R-io is methoxyl. In some embodiments, R10 is iso-butoxyl. In some embodiments of the pharmaceutical formulation of a compound of Formula I, X is C=0 and Y is absent. In such embodiments, the fused-ring structure comprises 9H-fluoren-9-one. In some embodiments, A and A' are each independently
Figure imgf000027_0001
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and
Figure imgf000027_0002
wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, A and A' are in the 2- and 7-positions of the 9H-fluoren- 9-one ring. In some embodiments, m and n are both zero; and R7 is H. In some embodiments, R8 is R< — N R 10 wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl. In some embodiments, Rg and R10 are both H. In some embodiments, R4 is H. In some embodiments, R is ethoxycarbonyl. In some embodiments of the pharmaceutical formulation of a compound of Formula I, X and Y are both C=0. In such embodiments, the fused-ring structure comprises 9,10-anthraquinone. In some embodiments, A and A' are each independently
Figure imgf000028_0001
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and
Figure imgf000028_0002
wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, m and n are both zero and R is H. In some embodiments, R8 is Re —
Figure imgf000028_0003
wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R11 is selected from the group consisting of H, alkyl, and aryl.
In some embodiments, Rg and R10 are both H. In some embodiments, R4 is H. In some embodiments of the pharmaceutical formulation of a compound of Formula I, X is N and Y is CH. In such embodiments, the fused-ring structure comprises acridine. In some embodiments, A and A' are each independently
Figure imgf000029_0001
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and
Figure imgf000029_0002
wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl. In some embodiments, A and A' are in the 3- and 6-positions of the acridine ring. In some embodiments, m and n are both zero; and R is H. In some embodiments, R8 is Re — N \ R 10 wherein: R9 and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl.
In some embodiments, Rg and R10 are both H. In some embodiments, R4 is H. In some embodiments of the pharmaceutical formulation of a compound of Formula I, the compound is selected from the group consisting of: 2,7-bis- guanidino-9H-fluorene; 2,7-bis-guanidinofluoren-9-one; 2,7-bis- guanidinoanthraquinone; 3,6-bis-guanidinoacridine; 2,7-bis-(ΛT- ethoxycarbonyl)guanidino-9H-fluorene; 2,7-bis(Λ/"- ethoxycarbonyl)guanidinofluoren-9-one; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/'- methyl)guanidino-9/-/-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-A/'- isopropyl)guanidino-9/-/-fluorene; 2,7-bis(/V"-ethoxycarbonyl-/V- methoxy)guanidino-9H-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/'- isobutoxy)guanidine-9H-fluorene; 2,7-bis(Λ/-methyl)guanidino-9/-/-fluorene; 2,7- bis(Λ/-iso-propyl)guanidino-9/-/-fluorene; 2,7-bis(Λ/-methoxy)guanidino-9/-/- fluorene; 2,7-bis(Λ/-isobutoxy)guanidine-9H-fluorene; 2,7- bis[(phenylimino)amino)]-9/- -fluorene; and 2,7-bis[(2-pyridylimino)amino)-9/-/- fluorene.
IV. Methods Of Treating Microbial Infections Subjects with microbial infections can be treated by methods described herein. These infections can be caused by a variety of microbes, including fungi, algae, protozoa, bacteria, and viruses. Exemplary microbial infections that can be treated by the method of the presently disclosed subject matter include, but are not limited to, infections caused by Trypanosoma species (e.g., Trypanosoma brucei rhodesiense), Pneumocytsis carnii, Giardia lamblia,
Cryptosporidium parvum, Cryptococcus neoformans, Candida albicans, Candida tropicalis, Salmonella typhimurium, Plasmodium falciparum, Leishmania donovani, and Leishmania mexicana amazonensis. The methods of the presently disclosed subject matter are useful for treating these conditions in that they inhibit the onset, growth, or spread of the condition, cause regression of the condition, cure the condition, or otherwise improve the general well-being of a subject afflicted with, or at risk of contracting the condition. Methods of treating microbial infections comprise administering to a subject in need of treatment an active compound as described herein. These active compounds, as set forth above, include compounds of Formula I, their corresponding prodrugs, and pharmaceutically acceptable salts of the compounds and prodrugs. With regard to the presently described method embodiments, compounds of Formula I are defined as having a structure as follows:
Figure imgf000031_0001
wherein: X and Y are each independently selected from the group consisting of CH, CH2, N, C=0, O, S and NR3, wherein R3 is selected from the group consisting of H, alkyl, aryl, alkoxyl, and aryloxyl, and Y can be present or absent; Ri and R2are each independently selected from the group consisting of H, alkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl; m and n are integers from 0 to 3, provided that when m is zero, Ri is an implied hydrogen, and when n is zero, R2 is an implied hydrogen; p and q are integers from 0 to 1 ; A and A' are each independently selected from one of:
Figure imgf000032_0001
wherein: R4, R5. Re, R7. and R8 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; or R5 and R6 together represent a C2 to C10 alkyl, hydroxyalkyl, or alkylene; or R8 is Re — N R 10 wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl; or a pharmaceutically acceptable salt thereof. In some embodiments of the method of treating a microbial infection by administering to a subject in need of treatment thereof a compound of
Formula I, X is CH2 and Y is absent. In such embodiments, the fused-ring structure comprises 9/-/-fluorene. In some embodiments, A and A' are each independently
Figure imgf000032_0002
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and 7Re — N \ R 10 wherein: R9 and Rι0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, A and A' are in the 2- and 7-positions of the 9H-fluorene ring. In some embodiments, m and n are both zero and R7 is H. In some embodiments, R4 is H and R8 is phenyl. In some embodiments, R4 is H and R8 is 2-pyridyl. In some embodiments, R8 is Re — N R io wherein: R9 and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, R4 and Rg are each H. In some embodiments, R4 is ethoxycarbonyl and R9 is H. In some embodiments, R-io is H. In some embodiments, Rι0 is methyl. In some embodiments, Rι0 is isopropyl. In some embodiments, Rι0 is methoxyl. In some embodiments, Rι0 is iso-butoxyl. In some embodiments of the method of treating a microbial infection by administering to a subject in need of treatment thereof a compound of
Formula I, X is C=0 and Y is absent. In such embodiments, the fused-ring structure comprises 9/-/-fluoren-9-one. In some embodiments, A and A' are each independently
Figure imgf000034_0001
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and Re — N R M,O wherein: Rg and Rι0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, A and A' are in the 2- and 7-positions of the 9H-fluoren- 9-one ring. In some embodiments, m and n are both zero and R7 is H. In some embodiments, R8 is Re — N Rιn wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
In some embodiments, Rg and Rio are both H. In some embodiments, R4 is H. In some embodiments, R4 is ethoxycarbonyl. In some embodiments of the method of treating a microbial infection by administering to a subject in need of treatment thereof a compound of Formula I, X and Y are both C=0. In such embodiments, the fused-ring structure comprises 9,10-anthraquinone. In some embodiments, A and A' are each independently
Figure imgf000035_0001
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and
Figure imgf000035_0002
wherein: Rg and R-io are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, m and n are both zero and R7 is H. In some embodiments, R8 is Re — N \ R 10 wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, Rg and Rι0 are both H. In some embodiments, R4 is H. In some embodiments of the method of treating a microbial infection by administering to a subject in need of treatment thereof a compound of
Formula I, X is N and Y is CH. In such embodiments, the fused-ring structure comprises acridine. In some embodiments, A and A' are each independently
Figure imgf000036_0001
wherein: p and q are each 1 ; R4 and R are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and R9 — N \ R 10 wherein: R9 and Rι0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, A and A' are in the 3- and 6-positions of the acridine ring. In some embodiments, m and n are both zero and R is H. In some embodiments, R8 is
Figure imgf000037_0001
wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl. In some embodiments, Rg and Rio are both H. In some embodiments, R is H. In some embodiments of the method of treating a microbial infection by administering to a subject in need of treatment thereof a compound of Formula I, the method comprises a compound of Formula I selected from the group consisting of: 2,7-bis-guanidino-9/- -fluorene; 2,7-bis-guanidinofluoren-9- one; 2,7-bis-guanidinoanthraquinone; 3,6-bis-guanidinoacridine; 2,7-bis-(Λ/"- ethoxycarbonyl)guanidino-9H-fluorene; 2,7-bis(Λ/"- ethoxycarbonyl)guanidinofluoren-9-one; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/- methyl)guanidino-9H-fluorene; 2,7-bis(/V"-ethoxycarbonyl-/V- isopropyl)guanidino-9H-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/'- methoxy)guanidino-9H-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/'- isobutoxy)guanidine-9H-fluorene; 2,7-bis(Λ/-methyl)guanidino-9/-/-fluorene; 2,7- bis(Λ/'-iso-propyl)guanidino-9H-fluorene; 2,7-bis(Λ/-methoxy)guanidino-9/-/- fluorene; 2,7-bis(Λ/'-isobutoxy)guanidine-9/-/-fluorene; 2,7- bis[(phenylimino)amino)]-9H-fluorene; and 2,7-bis[(2-pyridylimino)amino)-9rV- fluorene. In some embodiments, the compound of Formula I is administered in the form of a pharmaceutically acceptable salt. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt. In some embodiments, the microbial infection is selected from one of a Trypanosoma brucei rhodesiense infection and a Plasmodium falciparum infection. The subject treated in the presently disclosed subject matter in its many embodiments is desirably a human subject, although it is to be understood the methods described herein are effective with respect to all vertebrate species, which are intended to be included in the term "subject". The methods described herein are particularly useful in the treatment and/or prevention of infectious diseases in warm-blooded vertebrates. Thus, the methods can be used as treatment for mammals and birds. More particularly, provided is the treatment of mammals such as humans, as well as those mammals of importance due to being endangered (such as Siberian tigers), of economical importance (animals raised on farms for consumption by humans) and/or social importance (animals kept as pets or in zoos) to humans, for instance, carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and wild boars), ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses. Also provided is the treatment of birds, including the treatment of those kinds of birds that are endangered, kept in zoos, as well as fowl, and more particularly domesticated fowl, i.e., poultry, such as turkeys, chickens, ducks, geese, guinea fowl, and the like, as they also are of economical importance to humans. Thus, embodiments of the methods described herein include the treatment of livestock, including, but not limited to, domesticated swine (pigs and hogs), ruminants, horses, poultry, and the like.
Examples The following Examples have been included to illustrate modes of the presently disclosed subject matter. Certain aspects of the following Examples are described in terms of techniques and procedures found or contemplated to work well in the practice of the presently disclosed subject matter. In light of the present disclosure and the general level of skill in the art, those of skill can appreciate that the following Examples are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the scope of the presently disclosed subject matter.
Methods and Materials For Examples 1-4 Melting points were recorded using a Thomas-Hoover (Uni-Melt®
(Thomas Scientific, Swedesboro, New Jersey, United States of America)) capillary melting point apparatus and are uncorrected. TLC analysis was carried out on silica gel 60 F254 precoated aluminum sheets and detected under UV light. 1H and 13C- NMR spectra were recorded employing a Varian GX400 or Varian Unity Plus 300 spectrometer (Varian, Inc., Palo Alto, California,
United States of America), and chemical shifts (δ) are in ppm relative to TMS as internal standard. Mass spectra were recorded on a VG Analytical 70-SE spectrometer (VG Analytical, Ltd., Manchester, United Kingdom). Elemental analyses were obtained from Atlantic Microlab Inc. (Norcross, Georgia, United States of America) and are within ±0.4 of the theoretical values. The compounds reported as salts frequently analyzed correctly for fractional moles by water and/or ethanol of solvation. In each case 1H-NMR showed the presence of the indicated solvent(s). All chemicals and solvents (including anhydrous solvents) were purchased from Aldrich Chemical Co. (Milwaukee, Wisconsin, United States of America), Fisher Scientific (Fairlawn, New Jersey,
United States of America) or Frontier Scientific (Logan, Utah, United States of America) and used as purchased. Acetonitrile (CaH2) and triethylamine (CaH2) were distilled from the indicated drying agent. Synthesis of the bis- aminofluorenone (3b) and bis-aminoanthraquinone (3c) was achieved as described in Scheme 1 according to the literature. S-(2-naphthylmethyl) thioacetimidate was prepared adopting the reported procedure. Example 1 Scheme 1
Figure imgf000040_0001
HCI(g), EtOH, CH2CI2 Legend for compounds 2-5
Figure imgf000040_0002
Preparation of Bis(ΛT,Λ/"-di-BOCguanidino) Derivatives (General
Procedure) (Scheme 1). 2,7-Bis(AT,/V"-di-BOCguanidino)-9H-fluorene (4a). To a solution of 2,7-diamino fluorene (3a) (0.49 g, 2.5 mmol) in anhydrous OMF (15 mL) was added 1 ,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (1.56 g, 5.3 mmol), triethylamine (3.23 g, 32 mmol) and finally mercury(ll)chloride (1.57 g, 5.7 mmol). The suspension was kept stirring at room temperature for 24 h. The reaction, diluted with CH2CI2 and Na2C03 solution, was filtered through a pad of Celite. The organic layer was washed with water (3X) followed by brine and then dried over anhydrous Na2S0 . After evaporating the solvent to dryness the obtained residue was recrystallized from CH2CI2/MeOH giving a light yellow solid (1.15 g, 68%), mp >340 °C. 1H-NMR (CDCI3): δ 1.52, 1.54 (2s, 36H), 3.91 (s, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 8.4 Hz, 2H), 7.90 (s, 2H), 10.43 (s, 2H), 11.68 (s, 2H). 13C-NMR (CPCI3): δ 163.6, 153.5, 153.3, 144.2, 138.0, 135.2, 120.9, 119.7, 118.9, 83.6, 79.6, 37.2, 28.1 , 28.1. Anal. Calcd. for C35H48N608 (680.79): C % 61.75, H % 7.11 , N % 12.34. Found: C % 61.50, H
% 7.11 , N % 12.36. 2,7-Bis(Λ/',ΛT-di-BOCguanidino)fluoren-9-one (4b). Orange solid (1.16 g, 65%), mp >340 °C. 1H-NMR (COCI3): δ 1.51 , 1.54 (2s, 36H), 7.42 (d, J = 8.4 Hz), 7.77 (s, 2H), 7.82 (d, J = 8.4 Hz, 2H), 10.46 (br s, 2H), 11.63 (br s, 2H). 13C-NMR (CPCI3): δ 192.7, 163.3, 153.4, 153.2, 140.3, 137.4, 135.1 , 128.0, 120.5, 118.5, 84.0, 79.9, 28.1 , 28.0. Anal. Calcd. for C35H46N60g-
0.5H2O (703.78): C % 59.73, H % 6.73, N % 11.94. Found: C % 59.69, H % 6.76, N % 12.13. 2,7-Bis(ΛT,Λ/"-di-BOCguanidino)anthraquinone (4c). Yellow solid (1.24 g, 82%), mp > 340 °C. 1H-NMR (COCI3): δ 1.56 (s, 36H), 8.24 (s, 2H), 8.30 (d, J = 8.7 Hz, 2H), 8.43 (d, J = 8.7 Hz, 2H), 10.82 (br s, 2H), 11.62 (br s,
2H). 13C-NMR (CPCI3): δ 182.5, 181.2, 163.1 , 153.2, 142.3, 134.4, 129.4, 128.9, 126.7, 119.0, 84.4, 80.3, 28.1 , 28.0. Anal. Calcd. for C36H46N6Oιo- 0.5CH2CI2 (765.25): C % 57.28, H % 6.19. Found: C % 57.30, H % 6.09. 3,6-Bis(Λr,ΛT-di-BOCguanidino)acridine (4d). Canary yellow fluffy solid (0.88 g, 73%), mp > 340 °C. 1H-NMR (COCI3): δ 1.53, 1.55 (2s, 36H),
7.78 (dd, J = 2.1 Hz, J = 9.0 Hz, 2H), 7.9 (d, J = 9.0 Hz, 2H), 8.45 (d, J = 2.1 Hz, 2H), 8.6 (s, 1 H), 10.69 (s, 2H), 11.68 (s, 2H). Anal. Calcd. for C35H47N7θ8- 0.5H2O (702.79): C % 59.81 , H % 6.88, N % 13.95. Found: C % 59.97, H % 6.88, N % 13.90. Deprotection of ΛT,Λ/"-Di-BOCguanidines (General Procedure)
(Scheme 1). 2,7-Bis-guanidino-9H-fluorene Dihydrochloride (5a). The Λ/'Λ/"-di- BOC-guanidine (4a) (0.25 g, 0.4 mmol) was dissolved in CH2CI2 (10 mL), diluted with dry EtOH (15 mL) and the chilled solution was saturated with dry HCI. The reaction was then kept stirring at room temperature for 3 days (drying tube), when by the product started forming a precipitate over time. After evaporating the solvent to dryness, the residue was washed with ether multiple times and was dried under vacuum at 50-60 °C over night to give whitish yellow solid of the bis-guanidine dihydrochloride (0.13 g, quantitative), mp > 340 °C. 1H-NMR (OMSO-ofe): δ 3.95 (s, 2H), 7.24 (d, J = 8.4 Hz, 2H), 7.45 (s, 2H), 7.58
(br s, 8H), 7.95 (d, J = 8.4 Hz, 2H), 10.23 (br s, 2H). 13C-NMR (PMSO-d6): δ 156.1 , 156.1 , 144.5, 138.6, 133.8, 123.3, 121.4, 120.9, 36.8. MS (El): m/z 277 (M+ + 1 ) (14), 252 (100). Anal. Calcd. for C15H16N6-2HCI-0.25C2H5OH (364.76): C % 51.04, H % 5.39, N % 23.04, Cl % 19.44. Found: C % 50.74, H % 5.26, N % 22.99, Cl % 19.87. 2,7-Bis-guanidinofluoren-9-one Dihydrochloride (5b). Green solid (0.26 g, 89%), mp > 340 °C. 1H-NMR (PMSO-αf6): δ 7.45 (m, 4H), 7.68 (br s, 8H), 7.86 (d, J = 8.4 Hz, 2H), 10.25 (br s, 2H). 13C-NMR (PMSO-d6): δ 191.58,
159.03, 140.88, 136.54, 134.62, 130.77, 122.36, 119.86. MS (El): m/z 295 (M+ + 1 ) (23), 278 (100). Anal. Calcd. for C15H14N6O-2HCI-0.35H2O (373.53): C % 48.23, H % 4.51 , N % 22.49, Cl % 18.95. Found: C % 48.51 , H % 4.55, N % 22.13, Cl % 18.93. 2, 7-Bis-guanidinoanthraquinone Dihydrochloride (5c). Orange red solid (0.22 g, 91 %), mp >340 °C dec. 1H-NMR (PMSO-d6): δ 7.75 (d, J = 8.4 Hz, 2H), 7.97 (s, 2H), 8.06 (br s, 8H), 8.24 (d, J = 8.4 Hz, 2H), 10.87 (br s, 2H). 13C-NMR (PMSO-d6): δ 181.5, 180.4, 155.5, 142.0, 134.1 , 129.2, 128.9, 127.6, 119.3. MS (El): m/z 290 (M+) (3). Anal. Calcd. for Cι6Hι4N602-2HCI-1.66H20 (425.15): C % 45.20, H % 4.58, N % 19.77. Found: C % 45.24, H % 4.58, N %
19.47. 3,6-bis-guanidinoacridine Trihydrochloride (5d). Orange solid (0.33 g, 85%), mp >340 °C. 1H-NMR (PMSO-d6): δ 7.75 (dd, J = 8.4 Hz, 2H), 7.96 (d, J = 2.1 Hz, 2H), 8.06 ( br s, 8H), 8.23 (d, J = 8.4 Hz, 2H), 10.83 (br s, 2H). 13C- NMR (PMSO-c/6): δ 181.5, 180.4, 155.5, 142.0, 134.1 , 129.2, 128.9, 127.6,
119.3. Anal. Calcd. for C15H15N7-3HCI-C2H5OH-0.33H2O (454.72): C % 44.90, H % 4.46, N % 21.56. Found: C % 45.08, H % 5.10, N % 21.48.
Example 2 Scheme 2
Figure imgf000043_0001
NH2R, DIPEA, WSC, CH2CL2
Figure imgf000043_0002
Legends for compounds 7 Legends for compounds 8
7a R= H, X= CH2, R'= C02Et 8a R= Me, X= CH2, R'= H 7b R= H, X= C=0, R'= C02Et 8b R= -Pr, X= CH2, R'= H 7c R= Me, X= CH2, R'= C02Et 8c R= OMe, X= CH2, R'= H 7d R= i-Pr, X= CH2, R'= C02Et 8(1 R= O-i-Bu, X= CH2, R'= H 7e R= OMe, X= CH2, R'= C02Et 7f R= O-i-Bu, X= CH2, R'= C02Et Preparation of Carbamoyl Thiourea Derivatives (Scheme 2). 2,7-Bis(Λ/"-ethoxycarbonylthiourea)-9W-fluorene (6a). A solution of 2,7-diamino-9H-fluorene (3a) (1 g, 5.1 mmol) in CH2CI2 (10 mL), added to which ethyl isothiocyanatoformate (1.47 g, 11.2 mmol), was stirred at room temperature for 24 h. After flash chromatography, the reaction was diluted with hexane and the precipitate formed was collected and dried to yield the bis- carbamoylthiourea as a light brown solid (2.32 g, quantitative), mp >340 °C dec. 1H-NMR (PMSO-d6): δ 1.27 (t, J = 6.9 Hz, 6H), 3.95 (s, 2H), 4.23 (q, J = 6.9 Hz, 4H), 7.75 (d, J = 8.4 Hz, 2H), 7.89 (m, 4H), 11.28 (s, 2H), 11.64 (s, 2H). 13C-NMR (PMSO-d6): δ 163.2, 158.9, 143.6, 137.9, 135.8, 123.1 , 121.1 , 119.8, 59.5, 36.4, 28.0, 14.5. MS (El): m/z 459 (M+ + 1 , 18), 374.1 (8), 328 (100), 319
(8), 151 (12). 2,7-Bis(Λ "-ethoxycarbonylthiourea)fluoren-9-one (6b). To a suspension of 2,7-diaminofluorenone (3b) (0.3g, 1.4 mmol) in toluene (10 mL), was added 0.41 g (3.1 mmol) ethyl isothiocyanatoformate. The reaction mixture was refluxed for 10 h. After cooling to room temperature, the reaction was diluted with hexane. The orange precipitate obtained was filtered off, washed with hexane and dried under vacuum (0.66 g, 98 %), mp >340 °C dec. 1H-NMR (PMSO-d6): δ 1.26 (t, J = 7.2 Hz, 6H), 4.22 (q, J = 7.2 Hz, 4H), 7.69 (dd, J = 1.8, 8.1 Hz, 2H), 7.80 (d, J = 8.1 Hz, 2H), 7.97 (d, J = 1.8 Hz, 2H), 11.39 (s, 2H), 11.60 (s,2H). Preparation of Λ/-Substituted Carbamoyl Guanidines (General
Procedure) (Scheme 2). 2,7-Bis(Λ/"-ethoxycarbonyl)guanidino-9H-fluorene (7a). A stirred solution of carbamoyl thiourea (6a) (0.58 g, 1.2mmol), ammonia (0.5M solution in dioxane) (10 mL, 5.0 mmol), and diisopropylethylamine (0.98 g, 7.5 mmol) in anhydrous CH2CI2 (10 mL) was cooled to 0 °C. EPCI (0.96 g, 5.0 mmol) was added, and the solution was stirred at room temperature over night. The reaction mixture was washed with water (3X), followed by brine and dried over anhydrous Na2S04. The residue remaining after removal of the solvent was crystallized from EtOH/water (0.45 g, 84%), mp >340 °C. 1H-NMR (PMSO-d6): δ 1.16 (t, J = 7.2 Hz, 6H), 3.87 (s, 2H), 3.98 (q, J = 7.2 Hz, 4H), 7.33 (d, J = 8.4
Hz, 2H), 7.65 (s, 2H), 7.75 (d, J = 8.4 Hz, 2H), 9.31 (br s, 2H). 13C-NMR (PMSO-de): δ 163.1 , 159.0, 143.4, 136.8, 136.3, 120.4, 119.3, 118.3, 59.4, 36.4, 14.4. Anal. Calcd. for C21H24N6O4-0.5C2H5OH (447.48): C % 59.04, H % 6.08, N % 18.78. Found: C % 58.96, H % 5.74, N % 18.88. 2,7-Bis(Λ/"-ethoxycarbonyl)guanidinofluoren-9-one (7b). Brick red solid (0.35 g, 75%), mp >340 °C. 1H-NMR (PMSO-d6): δ 1.17 (t, J = 7.0 Hz, 6H), 4.00 (q, J = 7.0 Hz, 4H), 7.47 (dd, J = 1.8, 8.1 Hz, 2H), 7.59 (d, J = 8.1 Hz, 2H), 7.77 (d, J = 1.8 Hz, 2H), 9.31 (br s, 2H). 13C-NMR (PMSO-d6): δ 192.9, 162.5, 158.6, 139.6, 138.3, 134.1 , 126.4, 120.8, 116.6, 59.8, 14.5. Anal. Calcd. for C21H24N6O5-0.15CH2CI2 (451.17): C % 56.54, H % 5.08, N % 18.47.
Found: C % 56.30, H % 4.98, N % 18.62. 2,7-Bis(Λ/"-ethoxycarbonyl-Λ '-methyl)guanidino-9H-fluorene (7c). Adopting the same procedure followed for preparation of (7a), methylamine (2M solution in THF) was used for transformation of the thiourea compound into Λ/-substituted guanidine. The reaction yielded an off-white solid (0.53 g, 93%), mp 157-8 °C. 1H-NMR (PMSO-d6): δ 1.15 (t, J = 7.2 Hz, 6H), 2.83 (s, 6H), 3.90 (s, 2H), 3.94 (q, J = 7.2 Hz, 4H), 7.32 (d, J = 8.4 Hz, 2H), 7.54 (s, 2H), 7.83 (d, J = 8.4 Hz, 2H). 13C-NMR (PMSO-d6): δ 161.9, 157.9, 143.7,
137.6, 135.9, 123.1 , 121.0, 119.9, 59.9, 36.4, 28.3, 14.5. MS (FAB, thioglycerol): m/z 453 (M+ + 1 , 100), 407 (39), 323 (15). Anal. Calcd. for C23H28N604-H20 (470.52): C % 58.71 , H % 6.42, N % 17.86. Found: C % 58.81 , H % 6.39, N % 17.71. 2,7-Bis(Λ/"-ethoxycarbonyl-Λ/'-/so-propyl)guanidino-9H-fluorene
(7d). Using /so-propylamine and carrying out the same synthetic steps used for (7a), a beige solid was obtained (0.39 g, 88%), mp 142-4 °C. 1H-NMR (PMSO- d6): δ 0.84 (t, J = 7.2 Hz, 6H), 1.17 (m, 12H), 3.88 (s, 2H), 3.93 (q, J = 7.2 Hz, 4H), 4.11 (m, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.52 (s, 2H), 7.80 (d, J = 8.4 Hz, 2H). 13C-NMR (OMSO-d6): δ 163.4, 157.3, 143.5, 137.3, 136.2, 122.9, 120.9,
119.7, 59.6, 42.3, 36.4, 22.5, 14.5. MS (ES): m/z 509 (M+ + 1 ) (19), 255 (100). Anal. Calcd. for C27H36N6O4-0.25 C2H5OH (520.13): C % 63.50, H % 7.26, N % 16.15. Found: C % 63.20, H % 7.06, N % 16.35. 2,7-Bis(Λ "-ethoxycarbonyl-W-methoxy)guanidino-9H-fluorene (7e). Adopting the general procedure and using methylhydoxylamine, a tan white solid was obtained (0.55 g, 87%), mp 180-2 °C. 1H-NMR (OMSO-d6): δ 1.20 (t, J = 7.2 Hz, 6H), 3.68 (s, 6H), 3.76 (s, 2H), 4.10 (q, J = 7.2 Hz, 4H), 6.99 (d, J = 8.1 Hz, 2H), 7.16 (s, 2H), 7.35 (dd, J = 1.8, 8.1 Hz, 2H), 8.35 (s, 2H), 8.70 (s, 2H). 2,7-Bis(Λ/"-ethoxycarbonyl-Λ/'-isobutoxy)guanidino-9H-fluorene (7f).
Following the general procedure, O-isobutylhydroxylamine was used to prepare the target compound, which was obtained as creamy white crystals (0.8 g, 93%), 122-5 C; 1H-NMR (PMSO-d6) δ 0.88-0.99 (m, 30H), 1.21 (t, J = 7.2 Hz, 6H), 1.92-2.02 (m, 4H), 3.65 (d, J = 6.6 Hz, 8H), 3.74-3.78 (m, 4H), 3.85 (q, J = 7.2 Hz, 4H), 4.11 (q, J = 7.2 Hz, 4H), 7.00 (d, J = 8.1 Hz, 2H), 7.17 (s, 2H), 7.35
(d, J = 8.1 Hz, 2H), 7.55-7.62 (m, 6H), 8.19 (br s, 1 H), 8.21 (br s, 1 H), 8.67 (br s, 1 H), 8.68 (br s, 1 H), 9.01 (br s, 1 H), 9.02 (br s, 1 H), 9.10 (br s, 1 H), 9.11 (br s, 1 H); 13C-NMR (PMSO-d6) δ 154.0, 153.9, 153.3, 143.4, 143.3, 143.1 , 142.9, 142.9, 142.3, 142.2, 138.8, 138.6, 137.9, 137.7, 135.8, 135.6, 134.4, 134.2, 119.7, 119.4, 199.1 , 118.8, 117.7, 117.6, 116.6, 114.5, 79.5, 79.3, 61.1 , 60.4, 36.6, 36.5, 36.3, 27.3, 27.3, 19.3, 14.4; MS (ESI) m/z (rel. int.) 569 (M+ + 1 , 100). Anal. Calcd. for C2gH40N6O6 (568.66): C % 61.25, H % 7.08. Found: C % 61.12, H % 7.29. Preparation of Λ/-Substituted Guanidines (General Procedure) (Scheme 2). 2,7-Bis(ΛT-methyl)guanidino-9H-fluorene (8a). The substituted guanidine (7c) (0.5 g, 1.1 mmol) was suspended in EtOH (5 mL). 1 N KOH (11 mL, 11 mmol) was then added and the reaction mixture was kept stirring over night maintaining the temperature at 55-60 °C. The solvent was evaporated to dryness, the residue was washed multiple times with water and recrystallized from aqueous EtOH to give a light orange solid (0.24 g, 70%), mp 240-2 °C dec. 1H-NMR (PMSO-d6): δ 2.6 (s, 6H), 3.69 (s, 2H), 6.70 (d, J = 2.7 Hz, 2H), 6.90 (s, 2H), 7.50 (d, J = 2.7 Hz, 2H). For preparing the HCI salt, the free base was dissolved in dry EtOH (20 mL) and the solution was chilled in an ice-bath. After passing HCI gas for 10 min, the reaction was concentrated under reduced pressure and then diluted with ether. The precipitate formed was collected by filtration to give an orange solid (0.16 g, 65%), mp 276-8 °C. 1H-NMR (PMSO- d6): δ 2.84 (s, 6H), 3.96 (s, 2H), 7.25 (d, J = 8.4 Hz, 2H), 7.46 (s, 2H), 7.77 (br s, 2H), 7.89 (br s, 2H), 7.95 (d, J = 8.4 Hz, 2H), 10.01 (br s, 2H). 13C-NMR (PMSO-de): δ 155.6, 144.5, 138.5, 134.1 , 123.5, 121.5, 120.9, 36.5, 28.3. MS (ES): m/z 309 (M+ + 1 ) (100), 155 (9). Anal. Calcd. for C17H20N6-2HCI- 0.25C2H5OH-0.75H2O (406.33): C % 51.73, H % 6.20, N % 20.68. Found: C % 51.77, H % 6.24, N % 20.48. 2,7-Bis(Λ/-/so-propyl)guanidino-9rY-fluorene (8b). Free base: Starting with 7d and following the general procedure, a salmon orange solid (0.17 g, 79%), mp 247-9 °C dec. 1H-NMR (PMSO-d6): δ 1.11 (d, J = 5.4 Hz, 12H), 3.68 (s, 2H), 3.85 (m, 2H), 4.93 (br s, 4H), 5.38 (br s, 2H), 6.69 (d, J = 8.1 Hz, 2H), 6.89 (s, 2H), 7.49 (d, J = 8.1 Hz, 2H). Pihydrochloride salt: Shiny yellow crystals, mp 308-9 °C dec. 1H-NMR (PMSO-d6): δ 1.18 (d, J = 6.3 Hz, 12H), 3.94 (m, 4H), 7.23 (d, J = 8.4 Hz, 2H), 7.43 (s, 2H), 7.71 (br s, 4H), 7.93 (d, J = 8.4 Hz, 2H), 8.06 (br s, 2H), 9.88 (br s, 2H). 13C-NMR (PMSO-d6): δ 153.9, 144.8, 138.8, 134.5, 123.6, 121.6, 121.0, 43.8, 22.2. Anal. Calcd. for C21H28N6- 2HCI-1.5H20 (464.54): C % 54.31 , H % 7.16, N % 18.09. Found: C % 54.51 , H % 6.74, N % 17.79. 2,7-Bis(ΛT-methoxy)guanidino-9H-fluorene (8c). Free base: Using 7e as a starting material, a pink solid (0.17 g, 79%), mp 200-2 °C dec. 1 H-NMR
(PMSO-d6): δ 3.34 (br s, 4H), 3.74 (s, 2H), 5.29 (s, 6H), 7.20 (dd, J = 1.8, 8.1 Hz, 2H), 7.50 (m, 4H), 7.75 (br s, 2H). 13C-NMR (PMSO-d6): δ 151.6, 143.0, 139.5, 133.6, 118.7, 116.1 , 114.1 , 60.5, 36.5. Pihydrochloride salt: Shiny tan white solid, mp 264-7 °C dec. 1H-NMR (PMSO-d6): δ 1.18 (d, J = 6.3 Hz, 12H), 3.94 (m, 4H), 7.23 (d, J = 8.4 Hz, 2H), 7.43 (s, 2H), 7.71 (br s, 4H), 7.93 (d, J =
8.4 Hz, 2H), 8.06 (br s, 2H), 9.88 (br s, 2H). 13C-NMR (PMSO-d6): δ 153.9, 144.8, 138.8, 134.5, 123.6, 121.6, 121.0, 43.8, 22.2. Anal. Calcd. for C17H20N6O2-2HCI-0.6H2O (424.11 ): C % 48.14, H % 5.51 , N % 19.80. Found: C % 48.35, H % 5.38, N % 19.41. 2,7-Bis(Λ '-isobutoxy)guanidino-9H-fluorene (8d). Free base:
Starting with 7f and using the general procedure provided a brick red solid (0.16 g, 62%), mp 198-200 °C; 1H-NMR (PMSO-d6) δ 0.90 (d, J = 6.9 Hz, 12H), 1.93-2.02 (m, 2H), 3.55 (d, J = 6.9 Hz, 4H), 3.74 (s, 2H), 5.32 (br s, 4H), 7.21 (dd, J = 8.4, 1.8 Hz, 2H), 7.49-7.52 (m, 4H), 7.82 (br s, 2H); 13C-NMR (PMSO- d6) δ 151.5, 143.1 , 139.4, 133.8, 118.8, 116.3, 114.3, 79.1 , 36.5, 27.3, 19.3;
MS (ESI) m/z (rel. int.) 425 (M+ + 1 , 100), 245 (10), 156 (56); MS (ESI) m/z (rel. int.) 425 (M+ + 1 , 100), 254 (10), 156 (55). Hydrochloride salt: Pink solid, mp 251-2 °C (dec); 1H-NMR (PMSO-d6) δ 0.91 (d, J = 6.9 Hz, 12H), 1.97-2.06 (m, 2H), 3.65 (d, J = 6.9 Hz, 4H), 3.95 (s, 2H), 7.28 (d, J = 8.4 Hz, 2H), 7.48 (s, 2H), 7.96 (d, J = 8.4 Hz, 2H), 8.16 (br s, 4H), 10.36 (br s, 2H), 11.65 (br s, 2H).
Anal. Calcd. for C23H32N602-2HCI (496.21 ): C % 55.53, H % 6.88, N % 16.89. Found: C % 55.45, H % 6.87, N % 16.70. Example 3 Scheme 3
Figure imgf000048_0001
9a and b a R' = phenyl b R' = 2-pyridyl
Preparation of Reversed Amidines (General Procedure) (Scheme 3). 2,7-Bis[(phenylimino)amino]-9H-fluorene (9a). A solution of 2,7-diamino-9/-/- fluorene (0.3 g, 1.5 mmol) in dry MeCN (10 mL) was diluted with dry EtOH (15 mL) and chilled in an ice-water bath. The solution was then treated with S- (2-naphthymethyl)-thiobenzimidate hydrobromide (1.13 g, 3.2 mmol). Free base: The reaction was kept stirring at room-temperature for 24 h after which the solvent was evaporated to dryness leaving behind an oily residue that was triturated with ether to give a solid of the hydrobromide salt. The solid was then dissolved in EtOH, basified with 1 N NaOH and the free base extracted with EtOAc. After drying over Na2S04, the solvent was evaporated to dryness, giving an off white solid (0.45 g, 63%), mp 240-2 °C. 1 H-NMR (OMSO-d6): δ 3.83 (s, 2H), 6.31 (br s, 4H), 6.83 (m, 2H), 7.04 (s, 2H), 7.45 (d, J = 7.2 Hz, 6H), 7.71 (d, J = 8.1 Hz, 2H), 7.97 (d, J = 7.8 Hz, 4H). 13C-NMR (OMSO-d6): δ 153.9, 148.4, 143.7, 135.9, 135.7, 129.9, 127.9, 126.9, 120.2, 119.6, 118.3, 36.4. Hydrochloride salt: An ice-bath cold solution of the free base in Pry
EtOH was treated with HCI gas for 5-10 min, after which the solvent was concentrated to near dryness and the suspension was diluted with ether to furnish a yellow solid (0.28 g), mp 286-8 °C. 1H-NMR (PMSO-d6): δ 4.05 (s, 2H), 7.53 (d, J = 8.4 Hz, 2H), 7.68 (m, 4H), 7.79 (m, 4H), 7.96 (m, 2H), 8.16 (d, J = 8.4 Hz, 2H), 9.16 (br s, 2H), 9.86 (br s, 2H), 11. 67 (br s, 2H). 13C-NMR: δ
163.0, 144.9, 140.1 , 133.7, 133,6, 128.9, 128.6, 124.4, 122.4, 121.5, 36.95. MS (El): m/z 402 (M+, 100), 299 (38), 197 (9), 196 (60), 151 (7), 103 (32), 77 (10). Anal. Calcd. forC27H22N4-2HCI-0.25C2H5OH-H2O (504.94): C % 65.41 , H % 5.49, N % 11.09.CI % 14.04. Found: C % 65.76, H % 5.40, N % 10.87, Cl % 14.09. 2,7-Bis[(2-pyridylimino)amino]-9H-fluorene (9b). Free base: Shiny yellow crystals (0.70 g, 67%), mp 230-2 °C. 1 H-NMR (PMSO-d6): δ 4.74 (s, 2H), 6.56 (br s, 4H), 7.79 (d, J = 8.4 Hz, 2H), 7.99 (s, 2H), 8.41 (t, J = 7.8 Hz,
2H), 8.61 (d, J = 8.4 Hz, 2H), 8.81 (t, J = 7.8 Hz, 2H), 9.16 (d, J = 7.8 Hz, 2H), 8.48 (d, J = 7.8 Hz, 2H). Hydrochloride salt: Yellow solid (0.33 g), mp 302-4 °C. 1H-NMR (OMSO-de): δ 4.08 (s, 2H), 7.53 (d, J = 8.1 Hz, 2H), 7.74 (s, 2H), 7.85, (t, J = 7.5 Hz, 2H), 8.16 (d, J = 7.5 Hz, 2H), 8.21 (t, J = 7.5 Hz, 2 H), 8.58 (d, J = 7.5 Hz, 2H), 8.89 (d, J = 7.5 Hz, 2H), 9.39 (br s, 2H), 10.18 (br s, 2H). 13C-
NMR (PMSO-d6): δ 159.6, 149.7, 144.0, 143.8, 140.4, 138.4, 133.5, 128.6, 124.9, 124.2, 122.9, 121.8. MS (El): m/z 404 (M+, 100), 300 (28), 283 (6), 196 (33), 152 (9), 105 (28), 78(21 ). Anal. Calcd. forC25H2oN6-3.5HCI-0.33C2H5OH- H20 (565.29): C % 54.52, H % 4.89, N % 14.87.CI % 21.95. Found: C % 54.57, H % 4.74, N % 14.97, Cl % 21.87. Preparation of Amidines (General Procedure). The amidines are made by standard protocols starting with readily available dibromo analogs, which are converted into the corresponding bis- nitriles. The key intermediate bis-nitriles are converted into the amidines using the Pinner approach. For standard protocols for preparing amidines, see Pas,
B.P. et al.. J. Med. Chem. 1977, 20, 531 ; Bovkin. P.W. et al.. J. Med. Chem. 1995, 38, 912; and Ismail. M. et al. J. Med. Chem., 2003, 46, 4761-4769, which references are incorporated herein by reference. Example 4 Table 1 shows potent in vitro data for certain compounds of Formula I.
Two compounds (8a and 5b) show IC-50 values versus Trypanosoma brucei rhodesiense (T.b.r.) at 13 nM or less. Two compounds (5a and 8a) show IC-50 values versus Plasmodium falciparum (p.f.) at 10 nM or less. Compounds 8a and 8b give 3/4 and 4/4 cures versus the virulent STIP900 strain of T.b.r. in a mouse model. Prodrugs of these compounds hold promise as an oral treatment of both malaria and human African trypanosomiasis.
Figure imgf000050_0001
nil = absent; Me = methyl; Et = ethyl; /-Pr = isopropyl; -Bu = isobutyl; OMe = methoxyl; and 0/-Bu = isobutoxyl; a dashed line in the aromatic ring indicates that the bond is either present or absent, a) = NHR replaced by phenyl; b) = NHR replaced by 2-pyridyl. It will be understood that various details of the presently disclosed subject matter can be changed without departing from the scope of the presently disclosed subject matter. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.

Claims

CLAIMS What is claimed is: 1. A compound of Formula I:
Figure imgf000051_0001
wherein: X and Y are each independently selected from the group consisting of CH, CH2, N, C=0, O, S, and NR3, wherein R3 is selected from the group consisting of H, alkyl, aryl, alkoxyl, and aryloxyl, and Y can be present or absent; Ri and R2are each independently selected from the group consisting of H, alkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl; m and n are integers from 0 to 3, provided that when m is zero, Ri is an implied hydrogen, and when n is zero, R2 is an implied hydrogen; p and q are integers from 0 to 1 ; A and A' are each independently selected from one of:
Figure imgf000051_0002
wherein: R4, R5, Re, R7, and R8 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; or R5 and R6 together represent a C2 to C10 alkyl, hydroxyalkyl, or alkylene; or R8 is R9 — N \ R«> wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R11 is selected from the group consisting of H, alkyl, and aryl.
2. The compound of Claim 1 , wherein: X is CH2; and Y is absent.
3. The compound of Claim 2, wherein A and A' are each independently
Figure imgf000052_0001
wherein: p and q are each 1 ; R and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and
Figure imgf000052_0002
wherein: R9 and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
4. The compound of Claim 3, wherein: m and n are both zero; and R7 is H.
5. The compound of Claim 4, wherein: R4 is H; and R8 is phenyl.
6. The compound of Claim 4, wherein: R4 is H; and R8 is 2-pyridyl.
7. The compound of Claim 4, wherein R8 is R9 — N \ R 10 wherein: Rg and R 0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
8. The compound of Claim 7, wherein R4 and Rg are each H.
9. The compound of Claim 8, wherein R10 is H.
10. The compound of Claim 8, wherein R10 is methyl.
11. The compound of Claim 8, wherein R10 is isopropyl.
12. The compound of Claim 8, wherein R10 is methoxyl.
13. The compound of Claim 8, wherein R-io is iso-butoxyl.
14. The compound of Claim 7, wherein: R4 is ethoxycarbonyl; and R9 is H.
15. The compound of Claim 14, wherein R10 is H.
16. The compound of Claim 14, wherein R10 is methyl.
17. The compound of Claim 14, wherein R10 is isopropyl.
18. The compound of Claim 14, wherein R-io is methoxyl.
19. The compound of Claim 14, wherein Rio is iso-butoxyl.
20. The compound of Claim 1 , wherein: X is C=0; and Y is absent.
21. The compound of Claim 20, wherein A and A' are each independently
Figure imgf000054_0001
R7 wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and
Figure imgf000054_0002
wherein: Rg and R- are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
22. The compound of Claim 21 , wherein: m and n are both zero; and R7 is H.
23. The compound of Claim 22, wherein R8 is R9 — N \ R,„ wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R11 is selected from the group consisting of H, alkyl, and aryl.
24. The compound of Claim 23, wherein Rg and R10 are both H.
25. The compound of Claim 24, wherein R4 is H.
26. The compound of Claim 24, wherein R4 is ethoxycarbonyl.
27. The compound of Claim 1 wherein: X and Y are both C=0.
28. The compound of Claim 27, wherein A and A' are each independently
Figure imgf000055_0001
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and
Figure imgf000055_0002
wherein: R9 and R-ι0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn", wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
29. The compound of Claim 28, wherein: m and n are both zero; and R7 is H.
30. The compound of Claim 29, wherein R8 is R9 — N \ R 10 wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
31. The compound of Claim 30, wherein Rg and R-io are both H.
32. The compound of Claim 31 , wherein R4 is H.
33. The compound of Claim 1 , wherein: X is N; and Y is CH.
34. The compound of Claim 33, wherein A and A' are each independently
Figure imgf000056_0001
wherein: p and q are each 1 ; R and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and R9 — N \ R 10 wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
35. The compound of Claim 34, wherein: m and n are both zero; and R7 is H.
36. The compound of Claim 35, wherein R8 is
Figure imgf000057_0001
wherein: Rg and Rι0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
37. The compound of Claim 36, wherein Rg and Rio are both H.
38. The compound of Claim 37, wherein R4 is H.
39. The compound of Claim 1 , wherein the compound is selected from the group consisting of: 2,7-bis-guanidino-9H-fluorene; 2,7-bis-guanidinofluoren-9-one; 2,7-bis-guanidinoanthraquinone; 3,6-bis-guanidinoacridine; 2,7-bis-(Λ/"-ethoxycarbonyl)guanidino-9H-fluorene; 2,7-bis(ΛT-ethoxycarbonyl)guanidinofluoren-9-one; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/ -methyl )guanidino-9/-/-fluorene; 2, 7-bis(Λ/"-ethoxycarbonyl-Λ/ -isopropyl )guanidino-9H-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/'-methoxy)guanidino-9/-/-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/'-isobutoxy)guanidine-9H-fluorene; 2,7-bis(Λ/-methyl)guanidino-9 -/-fluorene; 2,7-bis(Λ/'-iso-propyl)guanidino-9/-/-fluorene; 2,7-bis(Λ/'-methoxy)guanidino-9/- -fluorene; 2,7-bis(Λ/-isobutoxy)guanidine-9/-/-fluorene; 2,7-bis[(phenylimino)amino)]-9 -/-fluorene; and 2,7-bis[(2-pyridylimino)amino)-9/-/-fluorene.
40. A pharmaceutically acceptable salt of a compound of Claim 1.
41. The pharmaceutically acceptable salt of Claim 40, wherein the salt is a hydrochloride salt.
42. A pharmaceutical formulation comprising: (a) a pharmaceutically acceptable carrier; and (b) a compound of Formula I:
Figure imgf000058_0001
wherein: X and Y are each independently selected from the group consisting of CH, CH2, N, C=0, O, S, and NR3, wherein R3 is selected from the group consisting of H, alkyl, aryl, alkoxyl, and aryloxyl, and Y can be present or absent; Ri and R2are each independently selected from the group consisting of H, alkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl; m and n are integers from 0 to 3; p and q are integers from 0 to 1 ; A and A' are each independently selected from one of:
Figure imgf000059_0001
wherein: R4> R5- RQ, R7. and R8 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; or R5 and R6 together represent a C2 to C10 alkyl, hydroxyalkyl, or alkylene; or R8 is
Figure imgf000059_0002
wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl; or a pharmaceutically acceptable salt thereof.
43. The formulation of Claim 42, wherein: X is CH2; and Y is absent.
44. The formulation of Claim 43, wherein A and A' are each independently
Figure imgf000059_0003
wherein: p and q are each 1 ; R4 and R are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and R9 — N \ R 10 wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
45. The formulation of Claim 44, wherein: m and n are both zero; and R7 is H.
46. The formulation of Claim 45, wherein: R4 is H; and R8 is phenyl.
47. The formulation of Claim 45, wherein: R4 is H; and R8 is 2-pyridyl.
48. The formulation of Claim 45, wherein R8 is
—
Figure imgf000060_0001
wherein: R9 and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
49. The formulation of Claim 48, wherein R4 and Rg are each H.
50. The formulation of Claim 49, wherein R10 s H.
51. The formulation of Claim 49, wherein R10 s methyl,
52. The formulation of Claim 49, wherein R10 s isopropyl.
53. The formulation of Claim 49, wherein R10 s methoxyl.
54. The formulation of Claim 49, wherein R10 s iso-butoxyl.
55. The formulation of Claim 48, wherein: R4 is ethoxycarbonyl; and Rg is H.
56. The formulation of Claim 55, wherein R10 s H.
57. The formulation of Claim 55, wherein R10 s methyl,
58. The formulation of Claim 55, wherein R10 s isopropyl.
59. The formulation of Claim 55, wherein Rι0 s methoxyl.
60. The formulation of Claim 55, wherein R10 s iso-butoxyl.
61. The formulation of Claim 42, wherein: X is C=0; and Y is absent.
62. The formulation of Claim 61 , wherein A and A' are each independently
Figure imgf000061_0001
wherein: p and q are each 1 ; R4 and R are each independently selected from the group consisting of H alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and R9 — N \ R in wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl.
63. The formulation of Claim 62, wherein: m and n are both zero; and R7 is H.
64. The formulation of Claim 63, wherein R8 is
Figure imgf000062_0001
wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
65. The formulation of Claim 64, wherein R9 and Rio are both H.
66. The formulation of Claim 65, wherein R4 is H.
67. The formulation of Claim 65, wherein R4 is ethoxycarbonyl.
68. The formulation of Claim 42 wherein: X and Y are both C=0.
69. The formulation of Claim 68, wherein A and A' are each independently
Figure imgf000062_0002
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and R9 — N \ R 10 wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
70. The formulation of Claim 69, wherein: m and n are both zero; and R7 is H.
71. The formulation of Claim 70, wherein R8 is
Figure imgf000063_0001
wherein: Rg and Rι0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
72. The formulation of Claim 71 , wherein Rg and Rι0 are both H.
73. The formulation of Claim 72, wherein R4 is H.
74. The formulation of Claim 42, wherein: X is N; and Y is CH.
75. The formulation of Claim 74, wherein A and A' are each independently
Figure imgf000064_0001
R7 wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and R9 — N \ R 10 wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
76. The formulation of Claim 75, wherein: m and n are both zero; and R7 is H.
77. The formulation of Claim 76, wherein R8 is R9 — N \ R 10 wherein: Rg and Rι0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn', and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
78. The formulation of Claim 77, wherein Rg and Rio are both H.
79. The formulation of Claim 78, wherein R is H.
80. The formulation of Claim 42, wherein the compound is selected from the group consisting of: 2,7-bis-guanidino-9H-fluorene; 2,7-bis-guanidinofluoren-9-one; 2,7-bis-guanidinoanthraquinone; 3,6-bis-guanidinoacridine; 2,7-bis-(Λ/"-ethoxycarbonyl)guanidino-9H-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl)guanidinofluoren-9-one; 2, 7-bis(Λ/"-ethoxycarbonyl-A/ -methyl )guanidino-9/-/-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/'-isopropyl)guanidino-9H-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/-methoxy)guanidino-9H-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/-isobutoxy)guanidine-9H-fluorene; 2, 7-bis(Λ/ -methyl )guanidino-9H-fluorene; 2,7-bis(Λ/-iso-propyl)guanidino-9/-/-fluorene; 2,7-bis(Λ/-methoxy)guanidino-9/-/-fluorene; 2,7-bis(Λ/'-isobutoxy)guanidine-9H-fluorene; 2,7-bis[(phenylimino)amino)]-9/-/-fluorene; and 2,7-bis[(2-pyridylimino)amino)-9 -/-fluorene.
81. A method of treating microbial infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula I:
Figure imgf000065_0001
wherein: X and Y are each independently selected from the group consisting of CH, CH2, N, C=0, O, S, and NR3, wherein R3 is selected from the group consisting of H, alkyl, aryl, alkoxyl, and aryloxyl, and Y can be present or absent; R and R2are each independently selected from the group consisting of H, alkyl, halo, hydroxyl, alkoxyl, aryloxyl, and aralkyloxyl; m and n are integers from 0 to 3; p and q are integers from 0 to 1 ; A and A' are each independently selected from one of:
Figure imgf000066_0001
wherein: R4, R5, Re, R7, and R8 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; or R5 and R6 together represent a C2 to C10 alkyl, hydroxyalkyl, or alkylene; or R8 is R9 — N \ R 10 wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: R11 is selected from the group consisting of H, alkyl, and aryl; or a pharmaceutically acceptable salt thereof.
82. The method of Claim 81 , wherein: X is CH2; and Y is absent.
83. The method of Claim 82, wherein A and A' are each independently
Figure imgf000067_0001
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and
Figure imgf000067_0002
wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
84. The method of Claim 83, wherein: m and n are both zero; and R7 is H.
85. The method of Claim 84, wherein: R4 is H; and R8 is phenyl.
86. The method of Claim 84, wherein: R4 is H; and R8 is 2-pyridyl.
87. The method of Claim 84, wherein R8 is
Figure imgf000068_0001
wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
88. The method of Claim 87, wherein R4 and Rg are each H.
89. The method of Claim 88, wherein Rio is H.
90. The method of Claim 88, wherein Rι0 is methyl.
91. The method of Claim 88, wherein Rio is isopropyl.
92. The method of Claim 88, wherein Rio is methoxyl.
93. The method of Claim 88, wherein Rι0 is iso-butoxyl.
94. The method of Claim 87, wherein: R4 is ethoxycarbonyl; and R9 is H.
95. The method of Claim 94, wherein Rio is H.
96. The method of Claim 94, wherein Rι0 is methyl.
97. The method of Claim 94, wherein Rι0 is isopropyl.
98. The method of Claim 94, wherein Rι0 is methoxyl.
99. The method of Claim 94, wherein Rι0 is iso-butoxyl.
100. The method of Claim 81 , wherein: X is C=0; and Y is absent.
101. The method of Claim 100, wherein A and A' are each independently
Figure imgf000068_0002
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and R9 — N \ R 10 wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
102. The method of Claim 101 , wherein: m and n are both zero; and R7 is H.
103. The method of Claim 102, wherein R8 is
Figure imgf000069_0001
wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
104. The method of Claim 103, wherein Rg and Rι0 are both H.
105. The method of Claim 104, wherein R4 is H.
106. The method of Claim 104, wherein R4 is ethoxycarbonyl.
107. The method of Claim 81 wherein: X and Y are both C=0.
108. The method of Claim 107, wherein A and A' are each independently
Figure imgf000070_0001
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and
Figure imgf000070_0002
wherein: R9 and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
109. The method of Claim 108, wherein: m and n are both zero; and R7 is H.
110. The method of Claim 109, wherein R8 is R9 — N \ R 10 wherein: Rg and Rι0 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; wherein: R11 is selected from the group consisting of H, alkyl, and aryl.
111. The method of Claim 110, wherein Rg and Rio are both H.
112. The method of Claim 111 , wherein R4 is H.
113. The method of Claim 81 , wherein: X is N; and Y is CH.
114. The method of Claim 113, wherein A and A' are each independently
Figure imgf000071_0001
wherein: p and q are each 1 ; R4 and R7 are each independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, aralkyl, hydroxyl, alkoxyl, hydroxyalkyl, hydroxycycloalkyl, alkoxycycloalkyl, aminoalkyl, acyloxyl, alkylaminoalkyl, and alkoxycarbonyl; and R8 is selected from the group consisting of aryl and
Figure imgf000071_0002
wherein: Rg and Rio are each independently selected from the group consisting of H, alkyl, aryl, and -ORn-, and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
115. The method of Claim 114, wherein: m and n are both zero; and R7 is H.
116. The method of Claim 115, wherein R8 is R9 — N \ R 10 wherein: Rg and R10 are each independently selected from the group consisting of H, alkyl, aryl, and -ORn; and wherein: Rn is selected from the group consisting of H, alkyl, and aryl.
117. The method of Claim 116, wherein Rg and Rio are both H.
118. The method of Claim 117, wherein R4 is H.
119. The method of Claim 81 , wherein the compound is selected from the group consisting of: 2,7-bis-guanidino-9/-/-fluorene; 2,7-bis-guanidinofluoren-9-one; 2,7-bis-guanidinoanthraquinone; 3,6-bis-guanidinoacridine; 2,7-bis-(Λ/"-ethoxycarbonyl)guanidino-9H-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl)guanidinofluoren-9-one; 2, 7-bis(Λ/"-ethoxycarbonyl-Λ/ -methyl )guanidino-9/-/-fluorene; 2, 7-bis(Λ/"-ethoxycarbonyl-Λ/ -isopropyl )guanidino-9/-/-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/-methoxy)guanidino-9/-/-fluorene; 2,7-bis(Λ/"-ethoxycarbonyl-Λ/-isobutoxy)guanidine-9H-fluorene; 2,7-bis(/v'-methyl)guanidino-9/-/-fluorene; 2,7-bis(Λ/-iso-propyl)guanidino-9/-/-fluorene; 2,7-bis(Λ/-methoxy)guanidino-9/-/-fluorene; 2,7-bis(Λ/-isobutoxy)guanidine-9/-/-fluorene; 2,7-bis[(phenylimino)amino)]-9/-/-fluorene; and 2,7-bis[(2-pyridylimino)amino)-9/- -fluorene.
120. The method of Claim 81 , wherein the compound of Formula I is administered in the form of a pharmaceutically acceptable salt.
121. The method of Claim 120, wherein the pharmaceutically acceptable salt is a hydrochloride salt.
122. The method of Claim 81 , wherein the microbial infection is selected from one of a Trypanosoma brucei rhodesiense infection and a Plasmodium falciparum infection.
PCT/US2004/038896 2003-11-24 2004-11-18 Fused ring dicationic anti-protozoan agents and their prodrugs WO2005051296A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04811591A EP1689705A4 (en) 2003-11-24 2004-11-18 Fused ring dicationic anti-protozoan agents and their prodrugs
JP2006541427A JP2007513888A (en) 2003-11-24 2004-11-18 Fused ring dicationic antiprotozoal agents and their prodrugs
CA002547972A CA2547972A1 (en) 2003-11-24 2004-11-18 Fused ring dicationic anti-protozoan agents and their prodrugs
AU2004292992A AU2004292992A1 (en) 2003-11-24 2004-11-18 Fused ring dicationic anti-protozoan agents and their prodrugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52501803P 2003-11-24 2003-11-24
US60/525,018 2003-11-24

Publications (2)

Publication Number Publication Date
WO2005051296A2 true WO2005051296A2 (en) 2005-06-09
WO2005051296A3 WO2005051296A3 (en) 2005-07-28

Family

ID=34632950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/038896 WO2005051296A2 (en) 2003-11-24 2004-11-18 Fused ring dicationic anti-protozoan agents and their prodrugs

Country Status (7)

Country Link
US (1) US7825279B2 (en)
EP (1) EP1689705A4 (en)
JP (1) JP2007513888A (en)
CN (1) CN1886367A (en)
AU (1) AU2004292992A1 (en)
CA (1) CA2547972A1 (en)
WO (1) WO2005051296A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158677B2 (en) 2007-06-01 2012-04-17 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2920775B1 (en) * 2007-09-07 2009-11-06 Pharma Hydro Dev P H D Soc Par NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, PROCESS FOR PREPARING THEM AND USES THEREOF.
US8277026B2 (en) * 2008-01-16 2012-10-02 Zamtec Limited Printhead cartridge insertion protocol
CA2934523A1 (en) 2013-12-24 2015-07-02 University Of Florida Research Foundation, Inc. Phenazine derivatives as antimicrobial agents
WO2017011730A2 (en) * 2015-07-15 2017-01-19 University Of Florida Research Foundation, Incorporated Phenazine derivatives as antimicrobial agents
US11053205B2 (en) 2017-02-17 2021-07-06 University Of Florida Research Foundation, Incorporated Phenazine derivatives as antimicrobial agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1374695A (en) * 1919-11-21 1921-04-12 Barrett Co Catalytic oxidation of fluorene
DE1014518B (en) * 1956-03-09 1957-08-29 Bayer Ag Process for coloring and printing polymers and copolymers of acrylonitrile or dicyanaethylene
US4141992A (en) * 1975-08-22 1979-02-27 American Cyanamid Company Cycloalkylcarboxyamidines and halobenzamidines as anti-amebic agents
US5521190A (en) * 1993-05-27 1996-05-28 Fmc Corporation Insecticidal pterdines and 8-deazapteridines
US5521189A (en) * 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5677349A (en) * 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases
US5668167A (en) * 1995-06-07 1997-09-16 Duke University Methods of treating microbial infections
AU6168296A (en) 1995-06-07 1996-12-30 The Administrators Of The Tulane Eductional Fund Chloroquine analogs and methods of preventing and treating p lasmodial disease
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
JP2003523927A (en) * 1998-08-20 2003-08-12 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Dicationic dibenzofuran and dibenzothiophene compounds and their use
CA2361734A1 (en) * 1999-01-26 2000-10-12 Andre Rosowsky Pharmaceutically active compounds and methods of use thereof
FR2796642B1 (en) * 1999-07-21 2001-10-19 Centre Nat Rech Scient QUATERNARY BIS-AMMONIUM SALT PRECURSORS AND THEIR APPLICATIONS AS PRODUCTS HAVING ANTI-PEST CONTROL ACTIVITY
JP2002097133A (en) * 2000-07-17 2002-04-02 Shionogi & Co Ltd Antimalaria agent and nematicidal agent containing triazene compound
WO2004006842A2 (en) * 2002-07-11 2004-01-22 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
ITMI20031754A1 (en) 2003-09-12 2005-03-13 Fabrizio Marcucci MICROBICIDE COMPOSITION.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1689705A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158677B2 (en) 2007-06-01 2012-04-17 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
EP2572712A2 (en) 2007-06-01 2013-03-27 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
EP2581081A2 (en) 2007-06-01 2013-04-17 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US9029413B2 (en) 2007-06-01 2015-05-12 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US9757407B2 (en) 2007-06-01 2017-09-12 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways

Also Published As

Publication number Publication date
EP1689705A2 (en) 2006-08-16
JP2007513888A (en) 2007-05-31
EP1689705A4 (en) 2007-08-29
US20050165044A1 (en) 2005-07-28
WO2005051296A3 (en) 2005-07-28
AU2004292992A1 (en) 2005-06-09
CA2547972A1 (en) 2005-06-09
US7825279B2 (en) 2010-11-02
CN1886367A (en) 2006-12-27

Similar Documents

Publication Publication Date Title
WO2005033065A1 (en) Novel amidine compounds for treating microbial infections
EP1745045A2 (en) NOVEL DICATIONIC IMIDAZO 1,2-a PYRIDINES AND 5,6,7,8-TE TRAHYDRO-IMIDAZO 1,2a PYRIDINES AS ANTIPROTOZOAL AGENTS
EP1726589B1 (en) 5,5&#39;-bis-(4-amidinophenyl)-2,2&#39;-bifuran derivatives and related compounds as antiprotozoal agent and prodrugs thereof
US8101636B2 (en) Linear dicationic terphenyls and their aza analogues as antiparasitic agents
US20080114047A1 (en) Cationic substituted benzofurans as antimicrobial agents
US20070276020A1 (en) Dicationic Compounds For Activity Against Trichomonas Vaginalis
US7825279B2 (en) Fused ring dicationic anti-protozoan agents and their prodrugs
US20100331368A1 (en) 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents
AU2003295923B2 (en) Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents
WO2005040132A1 (en) Dicationic triaryl analogs as anti-protozoan agents
US8188121B2 (en) Substituted pyridines as antiparasitic AZA teraryl compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480034750.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006541427

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2547972

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004292992

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2004292992

Country of ref document: AU

Date of ref document: 20041118

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004292992

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004811591

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004811591

Country of ref document: EP